Ltbr binding molecules and uses thereof

Abstract

Provided herein are anti-LTβR multispecific binding molecules, nucleic acids encoding the anti-LTβR multispecific binding molecules, vectors comprising the nucleic acids, host cells comprising the vectors, and pharmaceutical compositions comprising the anti-LTβR multispecific binding molecules. Also provided are methods of treating cancer in a subject in need thereof, the methods comprising administering the pharmaceutical compositions disclosed herein.

Description

093699.0208 LTΒR BINDING MOLECULES AND USES THEREOF CROSS-REFERENCES TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 634,038, filed April 15, 2024, the content of which is incorporated herein by reference in its entirety, and to which priority is claimed. SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in .xml format and is hereby incorporated by reference in its entirety. Said .xml file, created on April 15, 2025, is named 0936990208.xml and is 2,353,710 bytes in size. FIELD OF THE INVENTION This invention relates to anti- LTΒR binding molecules, nucleic acids and expression vectors encoding the binding molecules, recombinant cells containing the vectors, and compositions comprising the binding molecules. This invention further relates to anti- LTΒR multispecific binding molecules, nucleic acids and expression vectors encoding the binding molecules, recombinant cells containing the vectors, and compositions comprising the binding molecules. Methods of making the binding molecules, and methods of using the binding molecules to kill cancer cells, are also provided. BACKGROUND OF THE INVENTION Immunotherapy of cancer has the potential to improve the survival of cancer patients by promoting an immune response towards the tumor. While certain patients experience deep and long responses to currently available anti-cancer immunotherapy (e.g. anti-CTLA4 antibody ipilimumab, anti-PD-1 / PD-L1 antibodies such as pembrolizumab or nivolumab), a large fraction of patients do not benefit from the such therapies (Ribas et al., Science 359:1350-1355 (2018)). For instance, patients that have so called “cold” or non-inflamed tumors that are characterized by the lack of immune cell infiltrate or by the absence of an inflammatory signature have a lower benefit from anti-cancer immunotherapies (Chen and Mellman, Nature 541:321-30 (2017)). Thus, there is a need for novel anti-cancer immunotherapies to improve the efficacy in non-inflamed tumors. Targeting lymphotoxin-β receptor (LTβR) shows promise as a modality of enhancing treatment approaches in the field of cancer immunotherapy (Skeate, J. G., et al., 2020, Front Immunol, 11:922).093699.0208 The receptors of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) are particularly of interest as targets for immunotherapy. The TNFRs are characterized by a cysteine- rich domain (CRD) which can be found in their ectodomain in one to six copies (Locksley et al, Cell, 104:487-501 (2001)). The CRDs are involved in ligand binding but can also promote receptor self-assembly. The TNFRs become activated by ligands of the TNF superfamily (TNFSF) (Locksley et al, Cell, 104:487-501 (2001); Bodmer et al, Trends Biochem Sci, 27:19-26 (2002)). The TNFSF ligands (TNFLs) form a structurally comparatively homogeneous protein family and are characterized by a C-terminal TNF homology domain (THD), which promotes the assembly into homotrimeric, and in a few cases also into heterotrimeric, molecules (Bodmer et al, Trends Biochem Sci, 27:19-26 (2002)). In the trimeric state, the THD mediates the interaction with the receptors of the TNFRSF. The signaling competent TNFRs differ in their response to soluble ligand trimers. The group called category I TNFRs are robustly activated by soluble ligand trimers, while the anchoring-dependent mode of receptor activation has been demonstrated for several category II TNFRs. The region between the last CRD domain and the transmembrane domain of the receptor plays an important role in the activation by soluble ligand trimers, with receptors having a shorter region, among which is LTβR, being more readily activated by soluble ligand (category I TNFRs). Thus, it has been perceived that TNFR-type intrinsic properties, and not the quality of the ligand, determine the responsiveness of TNFRs to TNFLs. LTβR is a single-pass receptor that, like other TNFR superfamily members, is thought to exist as a trimer expressed on the cell surface and can be activated by binding either of its TNFSF ligands: LTα1b2 or LIGHT, primarily through the two central CRDs, while the N-terminal CRD may mediate formation of a signaling-inactive pre-ligand assembly state. Additionally, distinct regions within the cytoplasmic domain mediate self-interaction and the transmembrane helix itself may also regulate signaling (Sautes-Fridman, C., et al., 2019, Nat Rev Cancer, 19:307-325; Schumacher, T. N. & Thommen, D. S., 2022, Science, 375:eabf9419). While the minimal signaling unit of TNF receptors is a trimer and several mechanistic studies support the hypothesis that the efficiency of TNF receptor signaling is related to the degree of hexamer or higher-order network formation in the cell membrane (Vanamee, E.S. and Faustman, D.L., 2023, Frontiers in Immunology, 14:1225704; Fromm et al., 2023, Frontiers in Immunology, 14:1236332), unlike other TNF receptors, each LTβR subunit can bind only two sites in the LTα1β2 heterotrimer, the LTα-LTβ (higher affinity) and the LTβ-LTβ′ (lower affinity) interfaces for productive receptor activation (Sudhamsu, J., et al., 2013, Proc Natl Acad Sci USA, 110:19896-19901). Similarly, LIGHT has been shown to present only two high-affinity binding sites for LTβR (Eldredge, J., et093699.0208 al., 2006, Biochemistry, 45:10117-10128). Thus, the binding of LTα1β2 or LIGHT to LTβR brings two receptor molecules in close proximity and the LTβR self-interaction region in the cytoplasmic domain promotes receptor aggregation and consequent conformational changes (Force, W. R., et al., 2000, J Biol Chem, 275:11121-11129). When LTβR is activated within tumors it induces tumor cell apoptosis directly, as well as significant changes in the tumor microenvironment that are primarily driven through vascular normalization and generation of tertiary lymphoid structures (Rooney, I. A., et al., 2000, J Biol Chem, 275:14307-14315). These changes can synergize with methods that induce or support anti- tumor immune responses, such as checkpoint inhibitors and / or tumor vaccines, to greatly improve immunotherapeutic strategies against cancer. Despite lacking a cell death domain in its cytosolic tail, LTβR has been shown to induce death of cancer cell lines and to arrest tumor growth in cell line-derived xenograft models (Browning, J. L., et al., 1996, J Exp Med, 183:867-878; Lukashev, M., et al., 2006, Cancer Res, 66:9617-9624). LTβR activation was shown to lead to cell death in the presence of IFN-γ by either caspase-dependent (apoptosis) and / or caspase-independent (necroptosis / necrosis) mechanisms (Browning, J. L., et al., 1996, J Exp Med, 183:867-878; Kuai, J., et al., 2003, J Biol Chem, 278:14363-14369; Chen, M. C., et al., 2000, J Biol Chem, 275:38794-38801; Chen, M. C., et al., 278:16073-16081; Hu, X., et al., 2013, Carcinogenesis, 34:1105-1114; Wilson, C. A & Browning, J. L., 2002, Cell Death Differ, 9:1321-1333). In fact, at least two independent signaling pathways are initiated by LTβR ligation, LTβR cell death signaling and NF-κB activation (VanArsdale, T. L., et al., 1997, Proc Natl Acad Sci USA, 94:2460-2465). Most TNFRs contain one or more short binding motifs for proteins of the TNF receptor- associated factor (TRAF) family which link these TRAF-interacting TNFRs to intracellular signaling pathways enabling the activation of transcription factors of the NF-κB family and various MAP kinase cascades (Xie, 2013; Park, 2018). NF-κB activation and cell death induction are the best characterized events downstream LTβR. Unlike the prototypical TNF receptors, which activate the classical but not the alternative NF-κB pathway, LTβR binding by its ligands leads to both classical and alternative NF-κB pathway activation (Ganeff, C., et al., 2011, Mol Cell Biol, 31:4319-4334; Dejardin, E., et al., 2002, Immunity, 17:525-535). Ligand binding to LTβR can induce a rapid and transient activation of the classical NF-κB pathway, followed by a delayed activation of the alternative pathway (Dejardin, E., et al., 2002, Immunity, 17:525-535; Scheu, S., et al., 2002, J Exp Med, 195:1613-1624). The activation of one or the other NF-κB signaling pathway is spatially and temporally regulated by LTβR trafficking and varying levels of receptor cross-linking may be required for distinct conformational changes and activation of different signal093699.0208 transduction pathways controlling distinct patterns of gene expression and therefore differentially involved in various functions attributed to LTβR signaling (Ganeff, C., et al., 2011, Mol Cell Biol, 31:4319-4334; Dejardin, E., et al., 2002, Immunity, 17:525-535). Through activation of the classical NF-κB pathway, LTβR signaling promotes the upregulation of pro-inflammatory molecules, including the CCL4 / macrophage inflammatory protein (MIP)-1β, CXCL2 / MIP-2, and vascular-cell adhesion molecule 1 (VCAM-1), and CXCL1, CXCL2, intercellular adhesion molecule 1 (ICAM-1), VCAM-1, and E-selectin (Dejardin, E., et al., 2002, Immunity, 17:525-535; Madge, L. A., et al., 2008, J Immunol, 180:3467-3477). Conversely, the LTβR-mediated activation of alternative NF-κB pathway results in the production of lymphoid chemokines such as the CCL19 / EBl1-ligand chemokine (ELC), CCL21 / secondary lymphoid tissue chemokine (SLC), CXCL12 / stromal cell-derived factor-1α (SDF-1α), CXCL13 / B lymphocyte chemoattractant (BLC), and the cytokine B cell activation factor (BAFF), being all involved in lymphoid organogenesis and homeostasis (Dejardin, E., et al., 2002, Immunity, 17:525- 535; Seach, N., et al., 2008, J Immunol, 180:5384-5392). The signal transduction results in formation of the HEV, recruitment of immune cells, and organization of the nascent tertiary lymphoid structures (TLS), organized cell aggregates resembling secondary lymphoid organs that form in non-lymphoid tissues, such as cancer, in response to chronic inflammatory states (Sautes- Fridman, C., et al., 2019, Nat Rev Cancer, 19:307-325; Asrir, A., et al., 2022, Cell, 40:318-334; Vanhersecke, L., et al., 2021, Nat Cancer, 2:794-802). The core immune cohort is comprised of CD20+B cells, CD3+T cells, CD21+follicular dendritic cells, CD138+plasma cells, dendritic cells, CD66+neutrophils, CD68+macrophages, and high endothelial venules (HEVs) (Petitprez, F., et al., 2020, Front Immunol, 11:784). The presence of tumor-associated TLS is associated with more favorable prognosis in cancer patients and response to immune checkpoint therapies (Asrir, A., et al., 2022, Cell, 40:318-334; Vanhersecke, L., et al., 2021, Nat Cancer, 2:794-802). Activation of LTβR has the potential to promote TLS formation in the tumor microenvironment and induce anti- tumor immune responses and improve current cancer immunotherapies. In particularly in immune- non-inflamed deserted solid tumor phenotypes characterized by the lack of immune cell infiltrate or by the absence of an inflammatory signature (e.g. bladder, uterine, adrenocortical, and prostate tumors) (Sautes-Fridman, C., et al., 2019, Nat Rev Cancer, 19:307-325; ). Indeed, in preclinical studies, treatment with a bispecific antibody (bsAb) comprised of an anti-EGFR v-region paired with LIGHT, increased immune infiltrate leading to potent anti-tumor activity in models resistant to PD-1 blockade (Tang, H., et al., 2016, Cancer Cell, 30:500). TLS neogenesis may provide advantages over specific immune cell subset immunotherapies (e.g. T cell redirection), since it093699.0208 leads to infiltration of a diverse immune repertoire, including both innate and adaptive immune cells, that is more likely to overcome immune resistance. Several groups have targeted LTβR using its natural ligands LIGHT and LTα1β2 (Tang, H., et al., 2016, Cancer Cell, 30:500, Yu, P., et al., 2004, Nat Immunol, 5:141-149; Yu, P., et al., 2007, J Immunol, 179:1960-1968; Johansson-Percival, A., et al., 2017, Nat Immunol, 18:1207- 1217; Gurney et al. WO2018 / 119118). Whereas LTα1β2 is specific for LTβR, LIGHT also binds to and activates HVEM / TNFRSF14, a receptor expressed on and implicated in the regulation of immune cells (Pasero, C., et al., 2012, Curr Opin Pharmacol, 12:4778-485). LTβR-dependent downstream signaling can be initiated independently of ligand binding, either by receptor overexpression leading to self-association (Ganeff, C., et al., 2011, Mol Cell Biol, 31:4319-4334; Dhawan, P., et al., 2008, J Biol Chem, 283:15399-15408; Wu, M. Y., et al., 1999, J Biol Chem, 274:11868-11873), or artificially by anti-LTβR agonistic antibodies that induce receptor aggregation (Mackay, F., et al., 1996, J Biol Chem, 271:24934-24938; VanArsdale, T. L., et al., 1997, Proc Natl Acad Sci USA, 94:2460-2465). Due to the broad expression of LTβR in the organism, an agonistic LTβR-targeting drug capable of inducing signaling and creating an activating immune environment bears a substantial risk of causing systemic immune-related adverse events. Johansson-Percival et al. reported weight loss in mice after systemic administration of an LTβR activating compound, VTP-LIGHT (Johansson-Percival et al., Nat. Immunol. 18:1207-17 (2017)). Therefore, a therapeutic modality which activates LTβR specifically in the tumor but not in other tissues is needed to reduce the risk of toxicity and to generate a well-tolerated drug that can be employed for combination therapies. Typically, scFv domains recognizing a cell surface-exposed tumor antigen or tumor stroma antigen are used as anchor domain, but the suitability of other types of protein domains has been demonstrated as well (de Bruyn, M., et al., 2013, Cancer Lett, 332:175-183; Wajant, H., et al., 2013, Cancer Lett, 332:163-174; Wajant, H., et al., 2019, Cancers, 11(7):954). The use of an appropriate anchor domain allows the generation of fusion proteins which not only ensure full activation of TNFRSFs but also do this in a local fashion and / or link it with a second activity. The present invention meets this long felt, but unmet need. BRIEF SUMMARY OF THE INVENTION In some embodiments, the present invention provides bispecific antibodies or antigen binding fragments thereof comprising a first binding domain that specifically binds to a first antigen, and a second binding domain that specifically binds to a second antigen, wherein the first binding domain specifically binds to LTβR or a fragment or derivative thereof (LTβR-binding093699.0208 domain). In some embodiments, the antibody or antigen binding fragment thereof comprises one or two LTβR-binding domains. In some embodiments, the second binding domain that specifically binds to a second antigen specifically binds to a tumor-associated antigen (TAA; TAA-binding domain). In some embodiments, the TAA-binding domain specifically binds to Extra-Domain B (EDB), epidermal growth factor (EFGR), prostate-specific membrane antigen (PSMA), or mesothelin (MSLN). In some embodiments, the antibody or antigen binding fragment thereof comprises one or two EDB- binding domains. In some embodiments, the present invention provides multispecific antibodies or antigen binding fragments thereof comprising a first binding domain that specifically binds to a first antigen, and a second binding domain that specifically binds to a second antigen, and at least one additional domain which specifically binds to at least one more antigen, wherein the first binding domain is an LTβR-binding domain and the second binding domain is a TAA-binding domain. In some embodiments, the antibody or antigen binding fragment thereof comprises one or two LTβR- binding domains. In some embodiments, the TAA-binding domain selectively binds EDB, EGFR, PSMA, or MSLN. In some embodiments, the antibody or antigen binding fragment thereof comprises one or two EDB-binding domains. In some embodiments, the present invention provides antibodies or antigen binding fragments thereof comprising an LTβR-binding domain. In some embodiments, the antibody or antigen binding fragment thereof comprises one or two LTβR-binding domains. In some embodiments, the antibody or antigen binding fragment thereof comprises two LTβR-binding domains and further comprises K248 and T437R mutations in the Fc domain. In some embodiments, the present invention provides a nucleic acid molecule encoding a bispecific antibody or antigen binding fragment thereof, a multispecific antibody or antigen binding fragment thereof, or an antibody or antigen binding fragment thereof of the present invention. In some embodiments, the present invention provides a vector comprising a nucleic acid molecule of the present invention. In some embodiments, the present invention provides an isolated host cell comprising a nucleic acid molecule or vector of the present invention. In some embodiments, the present invention provides a pharmaceutical composition comprising a bispecific antibody or antigen binding fragment thereof a multispecific antibody or antigen binding fragment thereof, or an antibody or antigen binding fragment thereof of the present invention and a pharmaceutically acceptable carrier. In some embodiments, the present invention provides a method of producing a bispecific antibody or antigen binding fragment thereof, a multispecific093699.0208 antibody or antigen binding fragment thereof, or an antibody or antigen binding fragment thereof of to the present invention comprising the steps of: a) contacting a host cell with a nucleic acid molecule or vector of the present invention, culturing the host cell, and harvesting the molecule. In some embodiments, the present invention provides a method of treating a cancer in a subject comprising administering to the subject a bispecific antibody or antigen binding fragment thereof, a multispecific antibody or antigen binding fragment thereof, or an antibody or antigen binding fragment thereof of the present invention. In some embodiments, the method further comprises administering a second therapeutic agent selected from the group consisting of an anti- CD20 mAb, an anti-TIM-3 mAb, an anti-CTLA-4 antibody, an anti-PD-L1 antibody, an anti-PD-1 antibody, a PD-1 / PD-L1 therapy, Indoleamine-pyrrole 2,3-dioxygenase (IDO), an anti-OX40 antibody, an anti-GITR antibody, an anti-CD40 antibody, an anti-CD38 antibody, a cytokine, an oncolytic virus, a TLR agonist, a STING agonist, and combinations thereof. In some embodiments, the present invention provides a method of treating a cancer in a subject comprising administering to the subject a nucleic acid molecule or vector of the present invention. In some embodiments, the method further comprises administering a second therapeutic agent selected from the group consisting of an anti-CD20 mAb, an anti-TIM-3 mAb, an anti-CTLA- 4 antibody, an anti-PD-L1 antibody, an anti-PD-1 antibody, a PD-1 / PD-L1 therapy, Indoleamine- pyrrole 2,3-dioxygenase (IDO), an anti-OX40 antibody, an anti-GITR antibody, an anti-CD40 antibody, an anti-CD38 antibody, a cytokine, an oncolytic virus, a TLR agonist, a STING agonist, and combinations thereof. In some embodiments, the present invention provides a method of activating non-canonical NF-κB signaling in a subject in need thereof comprising administering to the subject a bispecific antibody or antigen binding fragment thereof, a multispecific antibody or antigen binding fragment thereof, or an antibody or antigen binding fragment thereof of the present invention. In some embodiments, the present invention provides a method of inducing tertiary lymphoid structure (TLS) neogenesis in a subject in need thereof comprising administering to the subject a bispecific antibody or antigen binding fragment thereof, a multispecific antibody or antigen binding fragment thereof, or an antibody or antigen binding fragment thereof of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS The following detailed description of embodiments of the invention will be better understood when read in conjunction with the appended drawings. It should be understood that the093699.0208 invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings. Figure 1, comprising Figure 1A through Figure 1O, depicts representative schematics of various antibody formats. Figure 1A depicts a schematic of a doubly conjugated Morrison-type antibody with two scFvs conjugated to the C-terminus of the Fc domain (Coloma MJ, Morrison SL. Design and Production of Novel Tetravalent Bispecific Antibodies. Nat. Biotechnol. 15(2) 2011:159–163; doi:10.1038 / nbt0297-159). Figure 1B depicts a schematic of a singly conjugated Morrison-type antibody with one scFv conjugated to the C-terminus of the Fc domain of a single heavy chain. Figure 1C depicts a schematic of a monovalent singly conjugated Morrison-type antibody with one Fc region and a single scFv conjugated to the C-terminus of the full-length heavy chain. Figure 1D depicts a schematic representation of a doubly conjugated monovalent Morrison- type antibody with one scFv conjugated to the C-terminus of the Fc and one scFv conjugated to the C-terminus of the full-length heavy chain. Figure 1E depicts a schematic of a doubly conjugated Morrison-type antibody with two scLIGHT trimers conjugated to the C-terminus of the Fc domain. Figure 1F depicts a schematic of a singly conjugated Morrison-type antibody with one scLIGHT trimer conjugated to the C-terminus of the Fc domain of a single heavy chain. Figure 1G depicts a schematic of a monovalent singly conjugated Morrison-type antibody with one Fc region and a single scLIGHT trimer conjugated to the C-terminus of the full-length heavy chain. Figure 1H depicts a schematic of a doubly conjugated monovalent Morrison-type antibody with one scLIGHT trimer conjugated to the C-terminus of the Fc and one scLIGHT trimer conjugated to the C- terminus of the full-length heavy chain. Figure 1I depicts a schematic of a doubly conjugated Fab antibody with an scFv conjugated to the N-terminus of each heavy chain. Figure 1J depicts a schematic of a singly conjugated monovalent antibody with an Fc and a single scFv conjugated to the N-terminus of the full-length heavy chain. Figure 1K depicts schematic of a monovalent antibody with a single scLIGHT trimer conjugated to the N-terminus of the Fc chain. Figure 1L depicts a schematic of a “wedged” bivalent antibody with a single scFv inserted between the C- terminus of a VH domain and the N-terminus of the Fc chain. Figure 1M depicts a schematic of a monovalent antibody with a single scFv fused to the N-terminus of an Fc chain. Figure 1N depicts a schematic of an scFv. Figure 1O depicts a schematic of a monoclonal antibody. Figure 2 depicts representative results of an E. coli-based evaluation of the anti-LTβR v- region in scFv format. The graph shows the magnitude of the ELISA response on the y-axis for the binding by the E9 scFv formatted as VL-linker-VH (LTΒRB132) or as VH-linker-VH (LTΒRB131). The negative controls included were an scFv (F5) that is known to form a stable093699.0208 scFv but does not bind LTβR and a media only control. Bars indicate the binding response after heat treatment at the indicated temperature. Figure 3, comprising Figure 3A through Figure 3C, depicts representative illustrations for hydrogen-deuterium exchange (HDX) based epitope mapping of the interaction between anti- LTβR E9 v-region or LIGHT, and LTβR. Figure 3A depicts a cartoon illustration of a model for the binding between LTβR and LIGHT based on PDB ID 4MXW and PDB ID 4J6G showing the two N-terminal CRDs in LTβR are primarily responsible for binding LIGHT. Figure 3B depicts representative maps of the HDX-derived epitope map of residues in LTβR that interact with either the E9 v-region (left) or LIGHT (right). Figure 3C depicts the residues in LTβR that interact with either the anti-LTβR E9 scFv (solid lines) or LIGHT (dashed lines) as indicated beneath the sequence of LTβR. Indicated domain boundaries are from Uniprot. The primary epitopes (thick lines) indicate residues whose HD-exchange rate were significantly altered upon binding and the secondary epitope (thin lines) indicate residues whose HD-exchange rate was modestly affected by binding. SEQ ID NO: 2477 is featured in Figure 3C. Figure 4 depicts a representative sequence alignment of the extracellular domain of LTβR in human, cynomolgus monkey, rat, and mouse. Residues that interact with the E9 v-region are highlighted in gray boxes. H.s. = Homo sapiens, M.f. = macaca fascicularis, R.n. = Rattus norvegicus, M.m. = Mus musculus. SEQ ID Nos: 2478-2481 are featured in Figure 4. Figure 5, comprising Figure 5A and Figure 5B, depicts representative HDX-based epitope mapping of the interaction between anti-EDB L19 v-region and EDB. Figure 5A depicts a representative map of the HDX-derived epitope map of residues in EDB that interact with the anti- EDB L19 v-region (sticks) shown on the FNIII-7-EDB-FNIII-8 structure (PDB ID 3T1W). Figure 6B depicts a representation of the residues in fibronectin that interact with the anti-EDB L19 v- region as indicated beneath the sequence of fibronectin. Indicated domain boundaries are from Uniprot. The primary epitopes (thick lines) indicate residues whose HD-exchange rate were significantly altered upon binding and the secondary epitope (thin lines) indicate residues whose HD-exchange rate was modestly affected by binding. SEQ ID NO: 2475 is featured in Figure 5B. Figure 6 depicts a representative sequence alignment of the fibronectin ED-B in human, cynomolgus monkey, rat, and mouse. Residues that interact with the anti-EDB L19 v-region are underlined. Thick lines indicate the major epitope and thin line indicates the minor epitope, based on HD-exchange MS. H.s. = Homo sapiens, M.f. = macaca fascicularis, R.n. = Rattus norvegicus, M.m. = Mus musculus. SEQ ID Nos: 2482-2485 are featured in Figure 6. Figure 7 depicts representative binding of MSLN × LTβR bispecific antibodies to human MSLN-expressing HGC27 and CT26-huMSLN cells, and MSLN-negative MCF-7 and CD26 cells,093699.0208 of which only HGC27 do not express LTβR. Receptor density data for MSLN and LTβR for these cell lines are listed in Table 14. Depicted are representative flow cytometry results of the dose range binding, represented by Alexa Fluor 488 (AF488) Geomean values, of MSLN × LTβR (MSLN-bivalent × LTβR-monovalent, LTBRB44; MSLN-bivalent × LTβR-bivalent, LTBRB145; MSLN-monovalent × LTβR-bivalent, LTBRB305) and the corresponding α-RSV × LTβR control antibodies (α-RSV-bivalent × LTβR-monovalent, LTBRB9; α-RSV-bivalent × LTβR-bivalent, LTBRB387), detected by AF488-labeled secondary anti-human Fc antibody. Figure 8, comprising Figure 8A and Figure 8B, depicts representative luciferase reporter assay results demonstrating the activation of NF-κB pathways by MSLN-bivalent × LTβR-bivalent (LTBRB145) compared to MSLN-bivalent × LTβR-monovalent (LTBRB383) and MSLN- monovalent × LTβR-bivalent (LTBRB305) bispecific antibodies and corresponding controls (α- RSV-bivalent × LTβR-monovalent, LTBRB9; α-RSV-bivalent × LTβR-bivalent, LTBRB387). Figure 8A depicts representative NF-κB activation, shown by fold induction of luminescence signal normalized to untreated control, when MSLN-expressing NCI-H596 cells were co-cultured with A549 NF-κB-luc reporter cells and stimulated for 16-20 hours by dose range of antibodies. Figure 8B depicts representative NF-κB activation, shown by fold induction of luminescence signal normalized to untreated control, when A549 NF-κB-luc reporter cells were stimulated for 16-20 hours by dose range of antibodies in the absence of MSLN-expressing cells. Figure 9, comprising Figure 9A and Figure 9B, depicts representative luciferase reporter assay results demonstrating the NF-κB activation in murine NIH / 3T3 NF-κB-luc reporter cells, by MSLN × LTβR and corresponding control α-RSV × LTβR. Figure 9A depicts representative NF- κB activation in NIH / 3T3 NF-κB-luc reporter cells (shown as fold induction of luciferase signal normalized to untreated control) cultured for 16-20 hours in the presence or absence of CT26 cells engineered to express human MSLN, by MSLN-bivalent × LTβR-bivalent antibody (LTBRB145) compared to corresponding control (α-RSV × LTβR, LTBRB387). Figure 9B depicts representative results demonstrating the NF-κB activation in NIH / 3T3 NF-κB-luc reporter cells cultured for 16-20 hours in the presence or absence of CT26 cells engineered to express human MSLN, by MSLN-bivalent × LTβR-monovalent antibody (LTBRB383) compared to corresponding control (α-RSV × LTβR, LTBRB381). Figure 10, comprising Figure 10A and Figure 10B, depicts representative luciferase reporter assay results demonstrating the activation of NF-κB pathways in A549 NF-κB-luc reporter cells at 16-20 hours of stimulation with MSLN × LTβR bispecific antibodies, including antibodies with Fc modifications that enhance clustering (RE). Figure 10A demonstrates the activation of NF- κB pathways in A549 NF-κB-luc reporter cells when co-cultured with MSLN-expressing NCI-093699.0208 H596 cells (shown as fold induction of luciferase signal normalized to untreated control) by MSLN × LTβR bispecific antibodies with RE modifications (MSLN-monovalent × LTβR-bivalent, LTBRB313; MSLN-bivalent × LTβR-bivalent, LTBRB148; MSLN-monovalent × LTβR- monovalent, LTBRB346; MSLN-bivalent × LTβR-monovalent, LTBRB169) compared to antibodies lacking the modifications (MSLN-monovalent × LTβR-bivalent, LTBRB305; MSLN- bivalent × LTβR-bivalent, LTBRB145; MSLN-monovalent × LTβR-monovalent, LTBRB338; and MSLN-bivalent × LTβR-monovalent, LTBRB383, respectively). Figure 10B depicts the activation of NF-κB pathways in A549 NF-κB-luc reporter cells when cultured alone or co-cultured with MSLN-expressing NCI-H596 cells (shown as fold induction of luciferase signal normalized to untreated control) by MSLN × LTβR RE-based Fc modified (LTBRB148, top panel) and unmodified (LTBRB145, middle panel), respectively, and rhLIGHT (bottom panel). Maximal fold induction and EC50 for co-culture setting are indicated on the graphs. Figure 11, comprising Figure 11A and Figure 11B, depicts representative luciferase reporter assay results demonstrating NF-κB activation in A549 NF-κB-luc reporter cells culturedin in huFn-7-EDB-8-9 (EDB+, 3µg / mL)-precoated plates , as a fold induction in luminescencesignal normalized to unstimulated control, by α-EDB-bivalent antibody-LIGHT fusion protein (LTBRB162) and EDB-bivalent × LTβR-monovalent (LTBRB384) and EDB-bivalent × LTβR- bivalent (LTBRB146) antibodies. Figure 11A depicts representative experimental results demonstrating NF-κB signaling induction in A549 NF-κB-luc reporter cells cultured for 16-20 hours by EDB × LTβR antibodies (LTBRB146 and LTBRB384) and their respective controls (α- RSV × LTβR, LTBRB381 and LTBRB387, respectively). Figure 11B depicts representative experimental results comparing NF-κB signaling induction with EDB × LTβR antibody (LTBRB146) and α-EDB × LIGHT fusion protein (LTBRB162), and their respective controls (α- RSV × LTβR, LTBRB387 and α-RSV × LIGHT, LTBRB162) in A549 NF-κB-luc reporter cells cultured for 16-20 hours. Figure 12 depicts representative luciferase reporter assay results demonstrating the time kinetics of NF-κB activation (represented by fold induction of luminescence signal normalized to unstimulated control) in A549 NF-κB-luc reporter cells cultured in huFn-7-EDB-8-9 (EDB+, 3µg / mL)-precoated plates, by EDB-bivalent × LTβR-bivalent antibody (LTBRB146), EDB- bivalent × LTβR-monovalent antibody (LTBRB384), α-EDB bivalent antibody-LIGHT fusion protein (LTBRB162) and α-EDB-bivalent × antibody-LTα1b2 fusion protein (LTBRB137) after 30 min, 1 hour, 2 hours, 4 hours and 6 hours stimulation. Figure 13 depicts representative results of the NF-κB non-canonical pathway (p100 and p52) activation in A549 cells, analyzed by JESS capillary Western blotting. Graph shows ratio093699.0208 between p52 and p100 protein area, normalized to unstimulated control cells, at indicated time points after stimulation with 20 ng / ml of TNF-α, EDB-bivalent × LTβR-bivalent antibody (LTBRB146, 10 nM) and α-EDB antibody-LIGHT fusion protein (LTBRB162, 10 nM). Figure 14 depicts representative results of the NF-κB non-canonical (p100 and p52, top panel) and canonical (phospho-p65, middle panel and phospho-IkBα, bottom panel) pathways activation in A549 cells, analyzed by JESS capillary Western blotting. The results are demonstrated as a ratio between p52 and p100 protein area (top panel), phosphor-p65 (middle panel) and a ratio between phospho-IkBα and total IkBα protein (bottom panel), all normalized to unstimulated control cells, at 4 hours after stimulation with various concentrations of TNF-α (right), EDB- bivalent × LTβR-bivalent antibody (LTBRB509), α-EDB antibody-LIGHT fusion protein (LTBRB162), EDB-bivalent × LTβR monovalent antibody (LTBRB384) and α-EDB × LTα1b2 fusion protein (LTBRB137)(left). Figure 15, comprising Figure 15A through Figure 15C, depicts representative results of cytokine release induction (interleukin 6 (IL-6), Figure 15A; interferon gamma-induced protein- 10 (IP-10), Figure 15B; and interferon-inducible T-cell alpha chemoattractant (ITAC), Figure 15C) in WI-38-132RA co-cultured with A375 for 24 hours by EDB × LTβR antibodies (LTBRB146 and LTBRB384) and their respective controls (α-RSV × LTβR, LTBRB381 and LTBRB387), and α- EDB antibody-LIGHT fusion protein (LTBRB162) and its control (α-RSV antibody-LIGHT, LTBRB29). Figure 16 depicts representative time course profiles of monocyte transmigration under flow through monolayer of pre-activated human umbilical vein endothelial cell (HUVEC) cultured on huFn-7-EDB-8-9 (EDB+, 3µg / mL)-precoated microscope flow chamber slide. HUVEC cells were pre-activated for 1 day with EDB-bivalent × LTβR antibodies, α-EDB antibody-LIGHT fusion protein (filled symbols, LTBRB146, LTBRB384, and LTBRB162, left, middle, and right, respectively) or control α-RSV × LTβR antibodies or α-RSV antibody-LIGHT fusion protein (LTBRB387, LTBRB381, and LTBRB29, left, middle, and right, respectively). Monocytes were flowed over activated HUVECs for 6 minutes, followed by a 50-minutes co-culture step with wash buffer, where monocytes were individually tracked and their positions marked at 1-minute intervals. Transmigration events were captured and counted per unit field. All experiments were carried out using triplicate fields and presented as a mean value with ± standard error measurements (± SEM). Figure 17 depicts representative results of a monocyte transmigration flow assay (described in Figure 16) demonstrating individual EC50profiles for EDB-bivalent × LTβR antibodies, α-EDB antibody-LIGHT fusion protein (filled symbols, LTBRB146, LTBRB384, and LTBRB162, left,093699.0208 middle, and right, respectively) or control α-RSV × LTβR antibodies or α-RSV antibody-LIGHT fusion protein (LTBRB387, LTBRB381, and LTBRB29, left, middle, and right, respectively) using AUC summary values of monocyte capture and transmigration. Profiles and non-linear fit calculated using GraphPad Prism 9.0 (Function: [Agonist] vs. response – variable slope). Figure 18 depicts representative effects of LTBRB401 (EDB-bivalent × LTβR-bivalent muIgG2a-AAS bispecific antibody) treatment either as monotherapy or in combination with α-PD- 1 antibody (clone RMP1-14) on growth of subcutaneous CT26 murine tumors. Group tumor volumes are graphed as the mean ± SEM (n = 10 mice / group). CT26 tumor cells were implanted on Day 0 (group mean tumor volumes 75 - 77 mm3), followed by biweekly treatment (intraperitoneally, IP) starting on Day 13 for total of 8 doses. Figure 19 depicts representative effects of LTBRB398 (EGFR-bivalent × LTβR-bivalent muIgG2a-AAS bispecific antibody) treatment either as monotherapy or in combination with α-PD- 1 antibody (clone RMP1-14) on growth of subcutaneous human EGFR-expressing CT26 (CT26- huEGFR) murine tumors. Group tumor volumes are graphed as the mean ± SEM (n=20 mice / group). CT26-huEGFR tumor cells were implanted on Day 0 (group mean tumor volumes 65.9-66.5 mm3), followed by biweekly treatment (intraperitoneally, IP) starting on Day 10 for total of 10 doses. Figure 20, comprising Figure 20A and Figure 20B, depicts representative effects of MSLN × LTβR muIgG2a-AAS bispecific antibodies treatment either as monotherapy or in combination with α-PD-1 antibody (clone RMP1-14) on growth of subcutaneous human MSLN-expressing murine tumors. Figure 20A depicts representative effects of LTBRB399 (MSLN-bivalent × LTβR- bivalent muIgG2a-AAS bispecific antibody) treatment either as monotherapy (at 10 mg / kg and 20 mg / kg IP) or in combination with α-PD-1 antibody (clone RMP1-14) on growth of subcutaneous human MSLN-expressing MC38 (MC38-huMSLN) murine tumors. Group tumor volumes are graphed as the mean ± SEM (n=10 mice / group). MC38-huMSLN tumor cells were implanted on Day 0 (group mean tumor volumes 66 and 67 mm3), followed by biweekly treatment (intraperitoneally, IP) starting on Day 13 for total of 8 doses. Figure 20B depicts representative effects of LTBRB399 (MSLN-monovalent × LTβR-bivalent muIgG2a-AAS bispecific antibody), LTBRB459 (MSLN-monovalent × LTβR-bivalent muIgG2a-AAS) and LTBRB435 (MSLN- monovalent × LTβR-monovalent muIgG2a-RE-AAS) bispecific antibodies treatment on growth of subcutaneous human MSLN-expressing CT26 (CT26-huMSLN) murine tumors. Group tumor volumes are graphed as the mean ± SEM (n=10 mice / group). CT26-huMSLN tumor cells were implanted on Day 0 (group mean tumor volumes 22 and 30 mm3), followed by biweekly treatment (intraperitoneally, IP) starting on Day 11 for total of 6 doses.093699.0208 DETAILED DESCRIPTION OF THE INVENTION Various publications, articles and patents are cited or described in the background and throughout the specification; each of these references is herein incorporated by reference in its entirety. Discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is for the purpose of providing context for the invention. Such discussion is not an admission that any or all of these matters form part of the prior art with respect to any inventions disclosed or claimed. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention pertains. Otherwise, certain terms used herein have the meanings as set forth in the specification. It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Unless otherwise stated, any numerical values, such as a concentration or a concentration range described herein, are to be understood as being modified in all instances by the term “about.” Thus, a numerical value typically includes ± 10% of the recited value. For example, a concentration of 1 mg / mL includes 0.9 mg / mL to 1.1 mg / mL. Likewise, a concentration range of 1% to 10% (w / v) includes 0.9% (w / v) to 11% (w / v). As used herein, the use of a numerical range expressly includes all possible subranges, all individual numerical values within that range, including integers within such ranges and fractions of the values unless the context clearly indicates otherwise. Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. Such equivalents are intended to be encompassedby the invention. As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains” or “containing,” or any other variation thereof, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers and are intended to be non-exclusive or open-ended. For example, a composition, a mixture, a process, a method, an article, or an apparatus that comprises a list of elements is not necessarily limited to only those elements but can include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus. Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For093699.0208 example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present). As used herein, the conjunctive term “and / or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and / or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one of these options is understood to fall within the meaning, and therefore satisfy the requirement of the term “and / or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and therefore satisfy the requirement of the term “and / or.” As used herein, the term “consists of,” or variations such as “consist of” or “consisting of,” as used throughout the specification and claims, indicate the inclusion of any recited integer or group of integers, but that no additional integer or group of integers can be added to the specified method, structure, or composition. As used herein, the term “consists essentially of,” or variations such as “consist essentially of” or “consisting essentially of,” as used throughout the specification and claims, indicate the inclusion of any recited integer or group of integers, and the optional inclusion of any recited integer or group of integers that do not materially change the basic or novel properties of the specified method, structure or composition. See M.P.E.P. § 2111.03. As used herein, “subject” means any animal, preferably a mammal, most preferably ahuman. The term “mammal” as used herein, encompasses any mammal. Examples of mammalsinclude, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guineapigs, monkeys, humans, etc., preferably a human. It should also be understood that the terms “about,” “approximately,” “generally,” “substantially,” and like terms, used herein when referring to a dimension or characteristic of a component of the preferred invention, indicate that the described dimension / characteristic is not a strict boundary or parameter and does not exclude minor variations therefrom that are functionally the same or similar, as would be understood by one having ordinary skill in the art. At a minimum, such references that include a numerical parameter would include variations that, using mathematical and industrial principles accepted in the art (e.g., rounding, measurement or other systematic errors, manufacturing tolerances, etc.), would not vary the least significant digit. The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences (e.g., anti- LTΒR bispecific antibodies and polynucleotides that encode093699.0208 them, anti- LTΒR / anti-EDB bispecific antibodies and polynucleotides that encode them, LTβR polypeptides and LTβR polynucleotides that encode them, EDB polypeptides and EDB polynucleotides that encode them), refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. For sequence comparison, typically one sequence acts as a reference sequence, to whichtest sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally, Current Protocols in Molecular Biology, F.M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)). Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol.215: 403-410 and Altschul et al. (1997) Nucleic Acids Res.25: 3389-3402, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching093699.0208 residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity × from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and × determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)). In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. A further indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions. As used herein, the term “polynucleotide,” synonymously referred to as “nucleic acid molecule,” “nucleotides” or “nucleic acids,” refers to any polyribonucleotide or polydeoxyribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA. “Polynucleotides” include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that can be single-stranded or, more typically, double-stranded or a mixture of single- and double- stranded regions. In addition, “polynucleotide” refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other093699.0208 reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. “Polynucleotide” also embraces relatively short nucleic acid chains, often referred to as oligonucleotides. As used herein, the term “vector” is a replicon in which another nucleic acid segment can be operably inserted so as to bring about the replication or expression of the segment. As used herein, the term “host cell” refers to a cell comprising a nucleic acid molecule of the invention. The “host cell” can be any type of cell, e.g., a primary cell, a cell in culture, or a cell from a cell line. In one embodiment, a “host cell” is a cell transfected with a nucleic acid molecule of the invention. In another embodiment, a “host cell” is a progeny or potential progeny of such a transfected cell. A progeny of a cell may or may not be identical to the parent cell, e.g., due to mutations or environmental influences that can occur in succeeding generations or integration of the nucleic acid molecule into the host cell genome. The term “expression” as used herein, refers to the biosynthesis of a gene product. The term encompasses the transcription of a gene into RNA. The term also encompasses translation of RNA into one or more polypeptides, and further encompasses all naturally occurring post-transcriptional and post-translational modifications. The expressed multispecific binding molecule, e.g. bispecific antibody, can be within the cytoplasm of a host cell, into the extracellular milieu such as the growth medium of a cell culture or anchored to the cell membrane. Preferably the multispecific binding molecule is secreted from production host cells into the culture medium. As used herein, the terms “peptide,” “polypeptide,” or “protein” can refer to a molecule comprised of amino acids and can be recognized as a protein by those of skill in the art. The conventional one-letter or three-letter code for amino acid residues is used herein. The terms “peptide,” “polypeptide,” and “protein” can be used interchangeably herein to refer to polymers of amino acids of any length. The polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.093699.0208 The peptide sequences described herein are written according to the usual convention whereby the N-terminal region of the peptide is on the left and the C-terminal region is on the right. Although isomeric forms of the amino acids are known, it is the L-form of the amino acid that is represented unless otherwise expressly indicated. A “multispecific binding molecule” as used herein means a molecule that specifically binds to at least two different molecules (e.g., a bispecific binding molecule binds two different molecules, a trispecific binding molecule binds three different molecules). Preferably, the molecule is a protein, for instance comprising an antibody or fragment or derivative thereof. A multispecific binding molecule or antibody of the invention has at least one binding domain specifically binding to LTΒR, and at least one binding domain specifically binding to a tumor-associated antigen, and in view of the presence of a binding specificity towards LTβR is sometimes referred to as “anti- LTΒR” binding molecule or antibody herein. As used herein, the term “valent” refers to the presence of a specified number of binding sites in an antigen-binding molecule. A natural antibody for example, or a full-length antibody, has two binding sites and is bivalent. As such, the terms “monovalent,” “trivalent,” “tetravalent,” “pentavalent,” and “hexavalent” denote the presence of one binding site, three binding sites, four binding sites, five binding sites, and six binding sites, respectively, in an antibody. Specificity and valency are independent of each other and should not be read as interchangeable. For example, a monospecific antibody will bind one specific molecule, however the antibody may have one binding site, two binding sites, three binding sites, four binding sites, five binding sites, six binding sites, or more binding sites for that specific molecule, i.e., a monospecific monovalent antibody, a monospecific bivalent antibody, a monospecific trivalent antibody, etc. Similarly, a bispecific antibody may have the same or different valency for both antigens the bispecific antibody binds to. For example, a bispecific antibody that binds EDB and LTβR (EDB × LTβR) may be bivalent (e.g., EDB-monovalent × LTβR-monovalent), trivalent (EDB-monovalent × LTβR-bivalent; EDB- bivalent × LTβR-monovalent), tetravalent (EDB-monovalent × LTβR-trivalent; EDB-bivalent × LTβR-bivalent; EDB-trivalent × LTβR-monovalent), pentavalent (EDB-monovalent × LTβR- tetravalent; EDB-bivalent × LTβR-trivalent; EDB-trivalent × LTβR-bivalent; EDB-tetravalent × LTβR-monovalent), etc. A “binding domain” as used herein means a functional part of a binding molecule, e.g. from an antibody, that confers specific binding of the binding molecule to a target molecule. Examples of binding domains are variable regions of antibodies that confer specific binding to a target molecule, and may be formed by more than one chain of an antibody, e.g. the variable domain of a heavy chain paired to the variable domain of a light chain, or by a single chain such093699.0208 as in scFv molecules, or e.g. a single domain such as VHH from llamas, e.g. nanobodies, etc. The target molecule of the present invention is LTβR or a tumor-associated antigen. The term “specific binding” as used herein refers to antibody binding to a predetermined antigen with greater affinity than for other antigens. Typically, the antibody binds to a predetermined antigen with a dissociation constant (KD) of about 1 × 10-7M or less, for example about 1 × 10-8M or less, about 1 × 10-9M or less, about 1 × 10-10M or less, about 1 × 10-11M or less, about 1 × 10-12M or less, about 1 × 10-13M or less or about 1 × 10-14M or less, typically with a KD that is at least tenfold less than its KD for binding to a non-specific antigen or epitope (e.g., BSA, casein). The dissociation constant can be measured using standard procedures. Antibodies that specifically bind to a predetermined antigen may, however, have cross-reactivity to other related antigens, for example to the same predetermined antigen from other species (homologs), such as human or monkey, for example Macaca fascicularis (cynomolgus, cyno) or Pan troglodytes (chimpanzee, chimp). The term “tumor associated antigen” or “TAA” as used herein means antigens present on tumor cells or present in the extracellular matrix of tumors, which antigens are not qualitatively different form antigens found on normal cells or in extracellular matrix of normal tissues, but which are quantitatively different in some respect, e.g. they are present on tumor cells or in the extracellular matrix of tumors in significantly greater amounts, in higher density, at a different site of expression, and / or are differentially accessible to the immune system, etc. In certain embodiments, the tumor associated antigen is present on tumor cells or in the tumor extracellular matrix in an at least two times higher amount as on non-tumor cells or extracellular matrix, more preferably an at least five times higher amount, such as e.g. an at least 10-times higher amount, even more preferably an at least 100-times higher amount, such as e.g. an at least 1000-times higher amount and most preferably an at least 10,000-times higher amount. EDB is present in fibronectin in the extracellular matrix of tumor tissue, whereas it is typically not detectable in fibronectin forms that are present in normal tissue (i.e. the same tissue under normal conditions and not being in a tumor environment). The term “extracellular matrix” as used herein means a non-cellular component present within all tissues and organs in the form of a three-dimensional network of extracellular macromolecules, such as collagen, enzymes, and glycoproteins, that provide structural and biochemical support of surrounding cells. Its exact composition varies for different tissues, but it is generally made up of proteoglycans, water, minerals, and fibrous proteins. A proteoglycan is composed of a protein core surrounded by long chains of starch-like molecules called glycosaminoglycans. Two main classes of extracellular matrix molecules make up the matrix:093699.0208 proteoglycans, and fibrous proteins, including for example collagen, elastin, fibronectin, and laminin. Antibodies The invention generally relates to anti- LTΒR multispecific binding molecules, nucleic acids and expression vectors encoding the multispecific binding molecules, recombinant cells containing the vectors, and compositions comprising the multispecific binding molecules. In preferred embodiments, the anti- LTΒR multispecific binding molecules are anti- LTΒR multispecific antibodies, such as anti- LTΒR bispecific antibodies or antigen binding fragments thereof. In certain embodiments, the anti- LTΒR multispecific binding molecules can comprise binding domains specifically binding to LTβR which binding domains are in a different format than antibodies or functional fragments thereof, e.g. they may comprise anti- LTΒR Fynomers, anti- LTΒR affimers, anti- LTΒR darpins, and / or other protein scaffolds screened for candidates that specifically bind to LTΒR. In multispecific binding molecules of the invention, the binding domain with specificity towards LTβR is not provided by LIGHT or LTα1β2 (natural ligands of LTΒR), nor functional fragments or derivatives thereof such as 3xhmLIGHT. In preferred embodiments a binding domain with specificity towards LTβR in the multispecific binding molecules of the invention comprise an antibody against LTΒR, preferably an agonistic antibody against LTΒR, or a functional fragment or derivative thereof, such as an scFv. Agonistic antibodies against LTβR as such have been described, and non-limiting examples are BHA10 (e.g. WO2004002431), and CBE11 (e.g. WO0230986), or can alternatively be generated according to known methods for antibody generation, such as immunization of mice, phage display, etc. Fyn SH3-derived polypeptides or ‘Fynomers’ are well known in the art and have been described e.g. in Grabulovski et al. (2007) JBC, 282, p. 3196-3204; WO 2008 / 022759; Bertschinger et al (2007) Protein Eng Des Sel 20(2):57-68; and Gebauer and Skerra (2009) Curr Opinion in Chemical Biology 13:245-255. The term "Fyn SH3-derived polypeptide", used interchangeably herein with the term "Fynomer", refers to a non-immunoglobulin-derived binding polypeptide (e.g. a so-called scaffold as described in Gebauer and Skerra (2009) Curr Opinion in Chemical Biology 13:245-255) derived from the human Fyn SH3 domain. Fynomers are small, about 7-kDa, globular polypeptides. The SH3 domain of the human Fyn kinase was successfully used as a scaffold to engineer proteins (Fyn SH3-derived binding proteins termed Fynomers) that bind with high affinity and specificity to different target proteins (WO 2008 / 022759, WO 2011 / 023685, WO 2013 / 135588, WO 2014 / 170063, Grabulovski D. et al., (2007) J Biol Chem093699.0208 282, p.3196-3204, Bertschinger J. et al. (2007) Protein Eng Des Sel, 20, p.57-68, and Schlatter et al. (2012) mAbs, 4(4) p.497-50). Affimer molecules are small proteins (12-14 kDa) that bind to target molecules with similar specificity and affinity to that of antibodies. These engineered non-antibody binding proteins are designed to mimic the molecular recognition characteristics of monoclonal antibodies in different applications (see e.g. Tiede et al, eLife 2017, DOI: 10.7554 / eLife.24903). DARPins (for designed ankyrin repeat proteins) are genetically engineered antibody mimetic proteins, typically exhibiting highly specific protein binding, and are derived from natural ankyrin proteins. They consist of at least three repeat motifs, and typically their molecular mass is about 14 or 18 kDa for four- or five-repeat DARPins, respectively. DARPin designs were for instance described in Binz et al, 2003, J. Mol. Biol.332: 489-503. Other binding protein formats, such as protein scaffolds, are known in the art and can also be used to provide one or more binding domains of certain embodiments of multispecific binding molecules of the invention. In preferred embodiments of the invention, the binding domain that binds to LTβR activates LTβR upon binding and is derived from an antibody, preferably an agonistic antibody, that specifically binds to LTΒR. In specific embodiments, the binding domain that binds to LTβR is a single chain variable domain (scFv) of an antibody, which scFv can be in any available format, e.g. stabilized by methods described previously and / or herein. The invention in certain embodiments relates to anti- LTΒR / anti-TAA multispecific antibodies or antigen-binding fragments thereof, nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and compositions comprising the multispecific antibodies. In certain embodiments, the anti- LTΒR / anti-TAA multispecific antibody or antigen-binding fragment is an anti- LTΒR / anti-EDB multispecific antibody or antigen-binding fragment. Methods of making the multispecific binding molecules and / or antibodies, and methods of using the multispecific binding molecules and / or antibodies to treat diseases, including cancer, are also provided. The multispecific binding molecules and / or antibodies disclosed herein possess one or more desirable functional properties, including but not limited to one or more of specific binding to LTβR and a TAA, high specificity to LTβR and a TAA, and / or the ability to treat or prevent cancer when administered alone or in combination with other anti-cancer therapies. As used herein, the term “antibody” is used in a broad sense and includes immunoglobulin or antibody molecules including human, humanized, composite and chimeric antibodies and antigen binding domains that are monoclonal or polyclonal. In general, antibodies are proteins or peptide chains that exhibit binding specificity to a specific antigen. Antibody structures are well093699.0208 known. Immunoglobulins can be assigned to five major classes (i.e., IgA, IgD, IgE, IgG and IgM), depending on the heavy chain constant domain amino acid sequence. IgA and IgG are further sub- classified as the isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4. Accordingly, the antibodies of the invention can be of any of the five major classes or corresponding sub-classes. Preferably, the antibodies of the invention are IgG1, IgG2, IgG3 or IgG4. Antibody light chains of vertebrate species can be assigned to one of two clearly distinct types, namely kappa and lambda, based on the amino acid sequences of their constant domains. Accordingly, the antibodies of the invention can contain a kappa or lambda light chain constant domain. According to particular embodiments, the antibodies of the invention include heavy and / or light chain constant regions from rat or human antibodies. In addition to the heavy and light constant domains, antibodies contain an antigen- binding region that is made up of a light chain variable region and a heavy chain variable region, each of which contains three domains (i.e., complementarity determining regions 1-3; CDR1, CDR2, and CDR3). The light chain variable region domains are alternatively referred to as LCDR1, LCDR2, and LCDR3, and the heavy chain variable region domains are alternatively referred to as HCDR1, HCDR2, and HCDR3. As used herein, the terms “variable region” and “variable domain” refer to the portions of the light and heavy chains of an antibody that include amino acid sequences of complementary determining regions (CDRs, e.g., CDR L1, CDR L2, CDR L3, CDR H1, CDR H2, and CDR H3) and framework regions (FRs). According to the methods used in this disclosure, the amino acid positions assigned to CDRs and FRs are defined according to Kabat (Sequences of Proteins of Immunological Interest, 5thEd. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a CDR (defined further herein) or FR (defined further herein) of the variable region. For example, a heavy chain variable region may include a single inserted residue (i.e., residue 52a according to Kabat) after residue 52 of CDR H2 and inserted residues (i.e., residues 82a, 82b, 82c, etc. according to Kabat) after residue 82 of heavy chain FR. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence. “Complementarity determining regions” (CDR) are antibody regions that bind an antigen. There are three CDRs in the VH (HCDR1, HCDR2, HCDR3) and three CDRs in the VL (LCDR1, LCDR2, LCDR3). CDRs may be defined using various delineations such as Kabat (Wu et al. (1970) J Exp Med 132: 211-50; Kabat et al., Sequences of Proteins of Immunological Interest, 5thEd. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), Chothia (Chothia093699.0208 et al. (1987) J Mol Biol 196: 901-17), IMGT (Lefranc et al. (2003) Dev Comp Immunol 27: 55- 77) and AbM (Martin and Thornton J Bmol Biol 263: 800-15, 1996). The correspondence between the various delineations and variable region numbering is described (see e.g., Lefranc et al. (2003) Dev Comp Immunol 27: 55-77; Honegger and Pluckthun, J Mol Biol (2001) 309:657-70; International ImMunoGeneTics (IMGT) database; Web resources, http: / / www_imgt_org). Available programs such as abYsis by UCL Business PLC may be used to delineate CDRs. The term “CDR”, “HCDR1”, “HCDR2”, “HCDR3”, “LCDR1”, “LCDR2” and “LCDR3” as used herein includes CDRs defined by any of the methods described supra, Kabat, Chothia, IMGT or AbM, unless otherwise explicitly stated in the specification. As used herein, the term an “isolated antibody” refers to an antibody which is substantially free of other antibodies having different antigenic specificities (e.g., an isolated bispecific antibody that specifically binds to LTβR is substantially free of bispecific antibodies that do not bind to LTβR; e.g., an isolated bispecific antibody that specifically binds to LTβR and / or EDB is substantially free of bispecific antibodies that do not bind to LTβR and / or EDB). In addition, an isolated antibody is substantially free of other cellular material and / or chemicals. As used herein, the term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that can be present in minor amounts. The monoclonal antibodies of the invention can be made by the hybridoma method, phage display technology, single lymphocyte gene cloning technology, or by recombinant DNA methods. For example, the monoclonal antibodies can be produced by a hybridoma which includes a B cell obtained from a transgenic nonhuman animal, such as a transgenic mouse or rat, having a genome comprising a human heavy chain transgene and a light chain transgene. In certain embodiments, monoclonal antibodies are produced by a recombinant host cell that expresses nucleic acid sequences encoding the antibody. Such a recombinant host cell can for instance be obtained by transfection of the nucleic acid sequences into a parent cell, e.g. a CHO cell. The recombinant host cell can be cultured under conditions conducive to expression of the antibody in the host cell, and the antibody can be isolated from the host cell, the culture medium, or both. In certain embodiments, a multispecific binding molecule of the invention comprises an antibody or one or more antigen-binding fragments thereof. As used herein, the term “antigen- binding fragment” refers to an antibody fragment such as, for example, a diabody, a Fab, a Fab', a F(ab')2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a bispecific dsFv (dsFv-dsFv'), a disulfide stabilized diabody (ds diabody), a single-chain antibody molecule (scFv), a single domain antibody (sdab) an scFv dimer (bivalent diabody), a multispecific antibody formed093699.0208 from a portion of an antibody comprising one or more CDRs, a camelized single domain antibody, a nanobody, a domain antibody, a bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not comprise a complete antibody structure. An antigen-binding fragment is capable of binding to the same antigen to which the parent antibody or a parent antibody fragment binds. According to particular embodiments, the antigen-binding fragment comprises a light chain variable region, a light chain constant region, and an Fd segment of the heavy chain. According to other particular embodiments, the antigen-binding fragment comprises Fab and F(ab’). “Fab” or “Fab fragment” refers to an antibody fragment composed of VH, CH1, VL and CL domains. In some embodiments, the antigen binding fragments include IgG-like molecules with complementary CH3 domains to force heterodimerization; recombinant IgG-like dual targeting molecules, wherein the two sides of the molecule each contain the Fab fragment or part of the Fab fragment of at least two different antibodies; IgG fusion molecules, wherein full length IgG antibodies are fused to an extra Fab fragment or parts of Fab fragment; Fc fusion molecules, wherein single chain Fv molecules or stabilized diabodies are fused to heavy-chain constant-domains, Fc-regions or parts thereof; Fab fusion molecules, wherein different Fab- fragments are fused together; ScFv- and diabody-based and heavy chain antibodies (e.g., domain antibodies, nanobodies) wherein different single chain Fv molecules or different diabodies or different heavy-chain antibodies (e.g. domain antibodies, nanobodies) are fused to each other or to another protein or carrier molecule. In some embodiments, IgG-like molecules with complementary CH3 domains molecules include the Triomab / Quadroma (Trion Pharma / Fresenius Biotech), the Knobs-in-Holes (Genentech), CrossMAbs (Roche) and the electrostatically-matched (Amgen), the LUZ-Y (Genentech), the Strand Exchange Engineered Domain body (SEEDbody)(EMD Serono), the Biclonic (Merus) or the DuoBody (Genmab A / S, see e.g. Labrijn et al, 2013, PNAS 110: 5145-5150). In some embodiments, the antigen binding fragments include “Stapled single chain Fv” or “spFv” refers to a scFv that comprises one or more disulfide bonds between the VH and the linker or the VL and the linker. Typically the spFv may comprise one disulfide bond between the VH and the linker, one disulfide bond between the VL and the linker, or two disulfide bonds between the VH and the linker and the VL and the linker. scFv molecules which comprise disulfide bonds between the VH and the VL are excluded from the term “spFv”. As used herein, the term “single-chain antibody” refers to a conventional single-chain antibody in the field, which comprises a heavy chain variable region and a light chain variable region connected by a short peptide, e.g. of about 15 to about 20 amino acids. As used herein, the term “single domain antibody” refers to a conventional single domain antibody in the field, which093699.0208 comprises a heavy chain variable region and a heavy chain constant region or which comprises only a heavy chain variable region. In certain embodiments, multispecific binding molecules of the invention comprise an antibody with one or more mutations in the Fc that abrogate binding to protein A. Such mutations facilitate purification of heterodimer, and have for instance been described in WO2010151792. As used herein, the term “human antibody” refers to an antibody produced by a human or an antibody having an amino acid sequence corresponding to an antibody produced by a human made using any technique known in the art. This definition of a human antibody includes intact or full-length antibodies, antigen-binding fragments thereof, and / or antibodies comprising at least one human heavy and / or light chain polypeptide. As used herein, the term “humanized antibody” refers to a non-human antibody that is modified to increase the sequence homology to that of a human antibody, such that the antigen- binding properties of the antibody are retained, but its antigenicity in the human body is reduced. As used herein, the term “chimeric antibody” refers to an antibody wherein the amino acid sequence of the immunoglobulin molecule is derived from two or more species. The variable region of both the light and heavy chains often correspond to the variable region of an antibody derived from one species of mammal (e.g., mouse, rat, rabbit, etc.) having the desired specificity, affinity, and capability, while the constant regions correspond to the sequences of an antibody derived from another species of mammal (e.g., human) to avoid eliciting an immune response in that species. As used herein, the term “multispecific antibody” refers to an antibody that comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment, the first and second epitopes do not overlap or do not substantially overlap. In an embodiment, the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In certain embodiments, a multispecific antibody comprises a third, fourth, or fifth immunoglobulin variable domain, or even more immunoglobulin variable domains. In an embodiment, a multispecific antibody is a bispecific antibody molecule, a trispecific antibody molecule, or a tetraspecific antibody molecule. As used herein, the term “bispecific antibody” refers to a multispecific antibody that binds no more than two epitopes, preferably no more than two antigens. A bispecific antibody is characterized by a first immunoglobulin variable domain which has binding specificity for a first epitope (e.g., an epitope on a LTβR antigen) and a second immunoglobulin variable domain that093699.0208 has binding specificity for a second epitope (e.g., an epitope on a tumor-associated antigen (TAA),). In an embodiment, a bispecific antibody comprises a first heavy chain variable domain and a first light chain variable domain which form a binding domain having binding specificity for a first epitope and a second heavy chain variable domain and a second light chain variable domain which form a binding domain having binding specificity for a second epitope. In an embodiment, a bispecific antibody comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In an embodiment, a bispecific antibody comprises a scFv, or fragment thereof, having binding specificity for a first epitope, and a scFv, or fragment thereof, having binding specificity for a second epitope. In an embodiment, a bispecific antibody comprises a scFv, or fragment thereof, having binding specificity for a first epitope, and a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a second epitope. In preferred embodiments of the invention, the first epitope is located on LTβR and the second epitope is located on a tumor-associated antigen (TAA), e.g., fibronectin, in particular EDB thereof. In certain embodiments, a multispecific binding molecule according to the invention comprises an antibody, e.g. an IgG, with an scFv fused to the antibody. The scFv may in certain embodiments have binding specificity for LTβR. Both arms (comprising the variable regions) of the antibody may in certain embodiments bind to a TAA (e.g., EDB of fibronectin). The scFv may be fused to a light chain of the antibody or to a heavy chain of the antibody, and may be fused to the N-terminus or to the C-terminus of the heavy or light chain. In certain embodiments, the scFv is fused to the N-terminus of the heavy chain. In other embodiments, the scFv is fused to the C- terminus of the heavy chain. It will be clear to the skilled person based on the instant disclosure that other forms are also possible, e.g., wherein a bispecific antibody comprising one arm specifically binding to LTβR and another arm specifically binding to a TAA is supplemented by fusing an scFv specifically binding to TAA to one of the chains of the antibody, etc. “Epitope" refers to a portion of an antigen to which an antibody specifically binds. Epitopes typically consist of chemically active (such as polar, non-polar or hydrophobic) surface groupings of moieties such as amino acids or polysaccharide side chains and may have specific three- dimensional structural characteristics, as well as specific charge characteristics. An epitope may be composed of contiguous and / or discontiguous amino acids that form a conformational spatial unit. For a discontiguous epitope, amino acids from differing portions of the linear sequence of the antigen come in close proximity in 3-dimensional space through the folding of the protein molecule. Antibody “epitope” depends on the methodology used to identify the epitope.093699.0208 As used herein, the term “ LTΒR” refers to a polypeptide that is a cell surface receptor for lymphotoxin involved in apoptosis and cytokine release, which is a member of the tumor necrosis factor receptor superfamily. LTβR can also be referred to as “tumor necrosis factor receptor superfamily member 3 (TNFRSF3).” LTβR is expressed on the surface of many cell types, including cells of epithelial and myeloid lineages. LTβR can specifically bind the lymphotoxin membrane form (a complex of lymphotoxin-alpha and lymphotoxin-beta). Activation of LTβR can trigger apoptosis via TRAF3 and TRAF5 and can lead to the release of interleukin 8. Unless noted, preferably the LTβR is a human LTβR. A human LTβR amino acid sequence is provided by UniProt number P36941. The term “TAA” or “tumor-associated antigen” refers to a protein or glycoprotein that is relatively restricted to tumor cells, including tumor-specific antigens (TSAs), capable of inducing an immune response. The term “EDB” or “extra domain B” refers to a domain of fibronectin that can be included in fibronectin molecules based on the splicing pattern of the fibronectin pre-mRNA. Extra domain B is a complete fibronectin (FN) type III repeat that comprises 91 amino acid residues. Generally, EDB is undetectable in normal adult tissues, but exhibits greater expression in fetal and tumor tissues in the extracellular matrix, and accumulates around neovasculature during angiogenic processes, thus making EDB a potential marker and target of angiogenesis. Unless noted, preferably EDB is a human EDB. A human EDB containing fibronectin isoform amino acid sequence is provided by UniProt number P02751. The term “fibronectin” refers to a polypeptide that is a high molecular weight glycoprotein of the extracellular matrix. Fibronectin can bind to membrane-spanning receptor proteins, referred to as integrins. Fibronectin can also bind other extracellular matrix proteins, such as collagen, fibrin, and heparan sulfate proteoglycans. Fibronectin can exist as a protein dimer, consisting of two nearly identical monomers linked by a pair of disulfide bonds. Fibronectin is produced from a single gene, but alternative splicing of the fibronectin pre-mRNA molecule leads to the creation of several isoforms of fibronectin, one of which is EDB fibronectin. Fibronectin can play a role in cell adhesion, growth, migration, and differentiation, and it can be important for processes such as wound healing and embryonic development. A human fibronectin amino acid sequence is provided by UniProt number P02751, which contains extra domain B, and NCBI Accession Numbers NP_001263337 (isoform (b), NP_001263338 (isoform (c), NP_001263339 (isoform (d), NP_001263340 (isoform (e), and NP_001263341 (isoform f), NP_001293058 (isoform 8), NP_001293059 (isoform 9), NP_001293060 (isoform 10), NP_001293061 (isoform 11), and NP_002017 (isoform 3).093699.0208 The terms "prostate specific membrane antigen" and "PSMA" are used interchangeably herein, and include any variants, isoforms and species homologs of human PSMA that are naturally expressed by cells. The complete amino acid sequence of human PSMA protein has the GenBank accession number NP_004467. The term “mesothelin,” as used herein, refers to any native, mature mesothelin which results from processing of a mesothelin precursor protein in a cell. The term includes mesothelin from any vertebrate source, including mammals such as primates (e.g. humans and cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term also includes naturally occurring variants of mesothelin, e.g., splice variants or allelic variants. The amino acid sequence of an exemplary human mesothelin precursor protein is shown in GenBank accession number NP_005814. “EGFR” or “Epidermal growth factor receptor” as used here refers to the human EGFR (also known as HER1 or ErbB1 having the amino acid sequence shown in GenBank accession number NP_005219, as well as naturally-occurring variants thereof. Such variants include well-known EGFRvIII and other alternatively spliced variants (e.g., as identified by SwissProt Accession numbers P00533-1 (wild type; identical to NP_005219), P00533-2 (F404L / L4055), P00533-3 (628-705: CTGPGLEGCP . . . GEAPNQALLR [SEQ ID NO: 2472] →PGNESLKAML . . . SVIITASSCH [SEQ ID NO: 2473] and 706-1210 deleted), P00533-4 (C628S and 629-1210 deleted), variants GlnQ98, R266, K521, 1674, G962, and P988, T790M, L858R / T790M and del(E746, A750). As used herein, an antibody or binding molecule that “specifically binds to LTΒR” refers to an antibody or molecule comprising an antigen binding domain thereof that binds to a LTβR, preferably a human LTβR, with a KD of 1 × 10−7M or less, preferably 1 × 10−8M or less, more preferably 5 × 10−9M or less, 1 × 10−9M or less, 5 × 10−10M or less, or 1 × 10−10M or less. The term “KD” refers to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e., Kd / Ka) and is expressed as a molar concentration (M). KD values for antibodies can be determined using methods in the art in view of the present disclosure. For example, the KD of an antibody can be determined by using surface plasmon resonance, such as by using a biosensor system, e.g., a BIACORE® system, or by using bio-layer interferometry technology, such as an Octet RED96 system. In preferred embodiments a binding domain with specificity towards LTβR in the multispecific binding molecules of the invention comprise an antibody against LTβR, preferably an agonistic antibody against LTβR, or a functional fragment or derivative thereof, such as an scFv. An “agonistic antibody against LTβR” as used herein is an antibody binding to LTβR and capable of inducing downstream signaling either directly or upon higher order clustering, e.g. by093699.0208 immobilization to a solid support, by use of cross-linking antibodies, etc. Agonistic antibodies against LTβR as such have been described, and non-limiting examples are BHA10 (e.g. WO2004002431), CBE11 (e.g. WO0230986), REA412 (commercially available from Miltenyi Biotec), 31G4D8 (commercially available from BioLegend), and 71319 / MAB629 (commercially available from Novus Biologicals), or can alternatively be generated according to known methods for antibody generation, such as immunization of mice, phage display, etc. The smaller the value of the KD of an antibody, the higher affinity that the antibody binds to a target antigen. In one aspect, provided herein is a binding agent comprising an antigen binding region that binds LTβR (e.g., human LTβR). In some embodiments, the present binding agent comprises at least one portion that is a polypeptide. In some embodiments, the present binding agent comprises at least one portion that is not a polypeptide. In some embodiments, the present binding agents are LTβR binding proteins. In some embodiments, the present disclosure provides binding agents (e.g., antibodies or proteins) that bind LTβR. In some embodiments, the LTβR binding agent binds an LTβR protein or a fragment thereof of a mammalian origin. In some embodiments, the LTβR binding agent binds a human LTβR protein or a fragment thereof. In some embodiments, the LTβR binding agent binds a LTβR protein or a fragment thereof originated from a non-human mammalian species. In some embodiments, the non-human mammalian species is a rodent (e.g., mice and rats). In some embodiments, the non-human mammalian species is a dog. In some embodiments, the non-human mammalian species is a cynomolgus monkeys (cynomolgus). In some embodiments, the binding agent comprises an antigen binding region that binds to LTβR. In some embodiments, the LTβR binding region in the present binding protein is an antibody or a binding domain derived from an antibody. In some embodiments, the antibody is a recombinant antibody. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the antibody is an IgG1 antibody. In some embodiments, the antibody is an IgG2 antibody. In some embodiments, the antibody is an IgG3 antibody. In some embodiments, the antibody is an IgG4 antibody. In some embodiments, the antibody comprises an IgG heavy chain. In some embodiments, the antibody comprises an IgG1 heavy chain. In some embodiments, the antibody comprises an IgG2 heavy chain. In some embodiments, the antibody comprises an IgG4 heavy chain. In some embodiments, the antibody comprises a kappa light chain. In some embodiments, the antibody comprises a kappa093699.0208 light chain constant region. In some embodiments, the antibody comprises a lambda light chain. In some embodiments, the antibody comprises a lambda light chain constant region. In some embodiments, the antibody is an antibody fragment comprising an antigen-binding site. In some embodiments, the antibody is an scFv. In some embodiments, the antibody is a disulfide-linked scFv. In some embodiments, the antibody is an spFv. In some embodiments, the antibody is a disulfide-linked sc(Fv)2. In some embodiments, the antibody is a Fab, Fab’, or a F(ab)2 antibody. In some embodiments, the antibody is a diabody. In some embodiments, the antibody is a nanobody. In some embodiments, the antibody is a monospecific antibody. In some embodiments, the antibody is a bispecific antibody. In some embodiments, the antibody is a trispecific antibody. In some embodiments, the antibody is a multispecific antibody. In some embodiments, the antibody is a monovalent antibody. In some embodiments, the antibody is a multivalent antibody. In some embodiments, the antibody is a bivalent antibody. In some embodiments, the antibody is a trivalent antibody. In some embodiments, the antibody is a tetravalent antibody. In some embodiments, the LTβR binding region provided herein binds to LTβR (e.g., human LTβR) with a dissociation constant (KD) of ≤ 1 μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM (e.g., 10-8M or less, e.g., from 10-8M to 10-13M, e.g., from 10-9M to 10-13M). In some embodiments, the LTβR binding region provided herein binds to LTβR with a dissociation constant of ≤ 0.01 nM. In some embodiments, the LTβR binding region provided herein binds to LTβR with a dissociation constant of ≤ 0.1 nM. In some embodiments, the LTβR binding region provided herein binds to LTβR with a dissociation constant of ≤ 0.5 nM. In some embodiments, the LTβR binding region provided herein binds to LTβR with a dissociation constant of ≤ 1.0 nM. In some embodiments, the LTβR binding region provided herein binds to LTβR with a dissociation constant of ≤ 1.5 nM. In some embodiments, the LTβR binding region provided herein binds to LTβR with a dissociation constant of ≤ 3.0 nM. A variety of methods of measuring binding affinity are known in the art, any of which can be used for purposes of the present disclosure, including by RIA, for example, performed with the Fab version of an antibody of interest and its antigen (Chen et al., 1999, J. Mol Biol 293:865-81); by biolayer interferometry (BLI) or surface plasmon resonance (SPR) assays by Octet®, using, for example, an Octet®Red96 system, or by Biacore®, using, for example, a Biacore®TM-2000 or a Biacore®TM-3000. An “on-rate” or “rate of association” or “association rate” or “kon” may also be determined with the same biolayer interferometry (BLI) or surface plasmon resonance (SPR) techniques described above using, for example, the Octet®Red96, the Biacore®TM-3000, or the Biacore®TM-8000 system.093699.0208 In some embodiments, provided herein are isolated anti-lymphotoxin beta receptor ( LTβR) monoclonal antibodies or antigen binding fragments thereof. In certain non-limiting embodiments, the binding domain that specifically binds to LTβR comprises an anti- LTβR antibody or a fragment or derivative thereof, for instance a single chain antibody fragment (scFv), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, and a HCDR3, and the VL comprises a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3, wherein said VH and VL comprise any of the following: (1) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:696, 697, and 698, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:699, 700, and 701, respectively; (2) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:743, 744, and 745, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:746, 747, and 748, respectively; (3) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:749, 750, and 751, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:752, 753, and 754, respectively; (4) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:749, 750, and 751, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:752, 753, and 754, respectively; (5) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:755, 756, and 757, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:758, 753, and 759, respectively; (6) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:725, 726, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:760, 729, and 730, respectively; (7) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:761, 762, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:764, 729, and 730, respectively; (8) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:765, 766, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:728, 729, and 767, respectively;093699.0208 (9) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:765, 766, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:728, 729, and 767, respectively; (10) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:768, 769, and 770, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:771, 772, and 773, respectively; (11) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:749, 774, and 775, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:776, 777, and 778, respectively; (12) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:779, 780, and 781, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:782, 783, and 784, respectively; (13) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:785, 786, and 787, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:788, 789, and 790, respectively; (14) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:749, 774, and 775, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:776, 753, and 791, respectively; (15) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:792, 793, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:794, 729, and 795, respectively; (16) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:792, 793, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:794, 729, and 795, respectively; (17) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:796, 797, and 798, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 800, and 801, respectively; (18) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:802, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:805, 806, and 807, respectively; (19) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:808, 809, and 810, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:811, 812, and 813, respectively;093699.0208 (20) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 818, and 819, respectively; (21) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:802, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 821, and 822, respectively; (22) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 824, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:825, 821, and 822, respectively; (23) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:826, 827, and 828, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 831, respectively; (24) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:832, 821, and 807, respectively; (25) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:826, 803, and 828, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 831, respectively; (26) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:833, 834, and 835, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:836, 837, and 838, respectively;, (27) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 839, and 819, respectively; (28) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:840, 841, and 807, respectively; (29) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 843, and 819, respectively; (30) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively;093699.0208 (31) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (32) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (33) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:808, 852, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:853, 830, and 848, respectively; (34) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:802, 854, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 821, and 822, respectively; (35) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:808, 855, and 856, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 857, and 858, respectively; (36) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:808, 809, and 810, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:811, 812, and 813, respectively; (37) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (38) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively;, (39) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:860, 861, and 862, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 863, and 822, respectively; (40) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:864, 865, and 866, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:867, 868, and 819, respectively; (41) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:869, 870, and 871, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 873, and 874, respectively;093699.0208 (42) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:875, 876, and 877, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 841, and 878, respectively; (43) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 879, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (44) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:880, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 859, and 819, respectively; (45) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 879, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (46) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:881, 882, and 883, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (47) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 859, and 819, respectively; (48) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:887, 888, and 889, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:890, 800, and 891, respectively; (49) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 892, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 894, respectively; (50) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:881, 882, and 883, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (51) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 892, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 894, respectively; (52) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:864, 865, and 866, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:867, 868, and 819, respectively;093699.0208 (53) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:881, 882, and 895, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (54) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively; (55) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (56) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:896, 897, and 898, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:899, 830, and 848, respectively; (57) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:849, 803, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 830, and 822, respectively; (58) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 901, and 819, respectively; (59) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:826, 902, and 903, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 807, respectively; (60) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (61) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively; (62) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (63) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively;093699.0208 (64) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:909, 910, and 911, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:912, 841, and 822, respectively; (65) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:914, 907, and 908, respectively; (66) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 915, and 916, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:917, 821, and 918, respectively; (67) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:914, 907, and 908, respectively; (68) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:919, 907, and 908, respectively; (69) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (70) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:849, 920, and 921, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:922, 923, and 924, respectively; (71) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:925, 926, and 927, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:928, 818, and 819, respectively; (72) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (73) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:869, 929, and 930, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:931, 907, and 932, respectively; (74) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively;093699.0208 (75) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (76) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:925, 926, and 927, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:928, 818, and 819, respectively; (77) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:933, 934, and 935, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:936, 818, and 937, respectively; (78) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:808, 938, and 939, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:940, 818, and 941, respectively; (79) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 943, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 863, and 945, respectively; (80) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:946, 947, and 948, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:949, 830, and 950, respectively; (81) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:951, 952, and 953, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:922, 837, and 954, respectively; (82) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (83) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 960, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (84) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:962, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (85) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 967, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively;093699.0208 (86) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:925, 968, and 969, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 830, and 970, respectively; (87) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 837, and 959, respectively; (88) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:749, 971, and 972, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:973, 974, and 975, respectively; (89) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 977, and 959, respectively; (90) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:978, 979, and 980, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 818, and 981, respectively; (91) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:982, 983, and 984, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:985, 986, and 932, respectively; (92) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 987, and 988, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (93) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 989, and 959, respectively; (94) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:990, 991, and 992, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:993, 821, and 994, respectively; (95) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 995, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 945, respectively; (96) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively;093699.0208 (97) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 987, and 996, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (98) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:925, 968, and 969, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 830, and 970, respectively; (99) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:997, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 857, and 945, respectively; SEQ ID NO:965, 857, and 945, respectively; (100) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (101) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 837, and 959, respectively; (102) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:946, 1000, and 1001, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1002, 821, and 1003, respectively; (103) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (104) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 1004, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively; (105) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 1005, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1006, 830, and 1007, respectively; (106) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 987, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (107) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:997, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 857, and 945, respectively;093699.0208 (108) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:962, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (109) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:743, 963, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (110) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 995, and 1008, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1009, 821, and 945, respectively; (111) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 1004, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively; (112) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1010, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (113) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 967, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1011, 1012, and 959, respectively; (114) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively; (115) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1013, 837, and 959, respectively; (116) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:779, 1014, and 1015, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1016, 1017, and 1018, respectively; (117) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1019, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1020, 837, and 959, respectively; (118) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1021, 987, and 1022, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1023, 1024, and 945, respectively;093699.0208 (119) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:942, 1005, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1006, 830, and 1007, respectively; (120) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1025, 1026, and 1027, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1028, 885, and 1029, respectively; (121) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:982, 983, and 984, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:985, 986, and 932, respectively; (122) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1030, 1031, and 1032, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 1033, and 1034, respectively; (123) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 1035, and 959, respectively; (124) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; ; or (125) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1036, 1037, and 1038, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1039, 1040, and 1041, respectively.

[0105] In some embodiments, provided herein are isolated anti-lymphotoxin beta receptor( LTΒR) monoclonal antibodies or antigen binding fragments thereof. In certain non-limiting embodiments, the binding domain that specifically binds to LTβR comprises an anti- LTΒR antibody or a fragment or derivative thereof, for instance a single chain antibody fragment (scFv), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH and VL comprises any of the following: (1) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:4, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:5; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:250, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:251; or (c) VH comprises an amino acid sequence having at least093699.0208 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:473, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:474; (2) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:20, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:21; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:264, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:265; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:487, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:488; (3) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:22, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:23; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:266, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:267; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:489, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:490; (4) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:24, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:25; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:268, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:269; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:491, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:492;093699.0208 (5) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:26, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:25; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:270, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:269; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:493, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:492; (6) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:27, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:28; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:271, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:272; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:494, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:495; (7) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:4, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:29; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:250, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:273; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:473, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:496; (8) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:30, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:31; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%,093699.0208 99%, or 100% identity to the amino acid sequence of SEQ ID NO:274, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:275; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:497, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:498; (9) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:32, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:33; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:276, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:277; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:499, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:500; (10) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:34, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:33; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:278, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:277; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:501, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:500; (11) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:35, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:36; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:279, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:280; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:502, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:503; (12) (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:37, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:38; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:281, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:282; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:504, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:505; (13) (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:39, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:40; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:283, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:284; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:506, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:507; (14) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:41, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:42; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:285, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:286; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:508, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:509; (15) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:37, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:43; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:281, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:287; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:504, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:510; (16) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:44, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:45; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:288, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:289; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:511, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:512; (17) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:44, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:46; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:288, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:290; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:511, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:513; (18) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:47, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:48; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:291, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:292; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:514, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:515; (19) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:49, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:50; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:293, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:294; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:516, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:517; (20) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:51, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:52; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:295, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:296; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:518, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:519; (21) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:53, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:54; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:297, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:298; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:520, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:521;093699.0208 (22) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:55, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:56; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:299, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:300; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:522, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:523; (23) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:57, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:58; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:301, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:302; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:524, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:525; (24) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:59, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:60; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:303, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:304; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:526, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:527; (25) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:61, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:62; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:305, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:306; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:528, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:529; (26) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:62, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:60; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:307, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:304; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:530, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:527; (27) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:64, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:65; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:308, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:309; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:531, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:532; (28) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:66, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:67; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:310, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:311; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:533, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:534; (29) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:68, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:69; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:312, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:313; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:535, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:536; (30) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:66, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:70; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:310, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:314; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:533, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:537; (31) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:71, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:72; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:315, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:316; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:538, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:539; (32) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:73, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:74; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:317, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:318; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:540, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:541; (33) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:75, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:76; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:319, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:320; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:542, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:543; (34) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:77, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:78; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:321, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:322; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:544, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:545; (35) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:79, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:56; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:323, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:300; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:546, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:523; (36) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:80, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:81; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:324, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:325; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:547, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:548; (37) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:82, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:52; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:326, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:296; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:549, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:519; (38) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:73, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:76; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:317, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:320; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:540, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:543;093699.0208 (39) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:83, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:84; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:327, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:328; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:550, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:551; (40) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:85, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:86; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:329, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:330; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:552, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:553; (41) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:87, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:88; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:331, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:332; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:554, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:555; (42) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:89, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:90; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:333, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:334; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:556, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:557; (43) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:91, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:92; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:335, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:336; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:558, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:559; (44) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:93, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:94; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:337, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:338; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:560, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:561; (45) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:95, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:96; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:339, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:340; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:562, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:563; (46) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:97, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:98; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:341, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:342; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:564, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:565; (47) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:99, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:100; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:343, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:344; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:566, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:567; (48) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:101, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:102; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:345, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:346; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:568, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:569; (49) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:103, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:104; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:347, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:348; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:570, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:571; (50) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:105, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:106; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:349, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:350; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:572, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:573; (51) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:99, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:107; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:343, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:351; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:566, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:574; (52) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:108, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:106; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:352, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:350; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:575, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:573; (53) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:109, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:110; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:353, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:354; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:576, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:577; (54) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:111, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:100; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:355, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:344; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:578, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:567; (55) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:112, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:72; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:356, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:316; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:538, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:539;093699.0208 (56) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:113, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:84; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:357, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:328; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:579, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:551; (57) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:114, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:115; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:358, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:359; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:580, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:581; (58) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:116, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:117; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:360, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:361; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:582, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:583; (59) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:113, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:118; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:357, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:362; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:579, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:584; (60) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:119, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:120; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:363, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:364; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:585, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:586; (61) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:121, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:84; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:365, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:328; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:587, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:551; (62) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:122, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:72; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:315, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:316; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:588, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:539; (63) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:123, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:124; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:366, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:367; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:589, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:590; (64) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:125, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:126; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:368, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:369; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:591, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:592; (65) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:127, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:128; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:370, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:371; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:593, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:594; (66) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:129, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:130; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:372, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:373; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:595, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:596; (67) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:131, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:132; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:374, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:375; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:597, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:598; (68) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:133, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:130; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:376, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:373; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:599, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:596; (69) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:134, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:135; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:377, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:378; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:600, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:601; (70) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:136, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:124; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:379, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:367; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:602, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:590; (71) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:137, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:138; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:380, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:381; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:603, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:604; (72) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:139, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:140; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:382, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:383; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:605, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:606;093699.0208 (73) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:141, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:124; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:384, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:367; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:607, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:590; (74) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:142, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:143; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:385, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:386; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:608, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:609; (75) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:144, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:145; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:387, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:388; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:610, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:611; (76) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:144, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:124; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:387, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:367; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:610, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:591; (77) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:146, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:140; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:389, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:383; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:612, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:606; (78) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:147, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:148; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:390, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:391; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:613, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:614; (79) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:149, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:150; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:392, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:393; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:615, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:616; (80) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:151, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:152; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:394, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:395; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:617, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:618; (81) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:153, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:154; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:396, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:397; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:619, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:620; (82) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:155, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:156; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:398, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:399; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:621, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:622; (83) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:157, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:158; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:400, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:401; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:623, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:624; (84) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:159, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:160; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:402, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:403; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:625, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:626; (85) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:161, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:162; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:404, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:405; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:627, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:628; (86) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:163, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:164; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:406, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:407; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:629, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:630; (87) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:165, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:166; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:408, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:409; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:631, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:632; (88) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:167, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:168; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:410, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:411; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:633, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:634; (89) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:169, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:170; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:412, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:413; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:635, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:636;093699.0208 (90) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:171, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:172; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:414, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:415; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:637, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:638; (91) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:173, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:174; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:416, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:417; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:639, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:640; (92) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:175, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:176; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:418, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:419; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:641, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:642; (93) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:177, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:178; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:420, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:421; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:643, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:644; (94) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:179, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:180; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:422, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:423; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:645, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:646; (95) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:181, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:182; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:424, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:425; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:647, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:648; (96) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:183, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:184; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:426, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:427; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:649, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:650; (97) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:185, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:186; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:428, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:429; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:651, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:652; (98) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:187, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:178; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:430, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:421; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:653, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:644; (99) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:165, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:188; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:408, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:431; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:631, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:654; (100) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:189, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:190; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:432, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:433; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:655, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:656; (101) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:185, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:191; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:428, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:434; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:651, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:657; (102) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:192, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:193; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:435, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:436; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:658, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:659; (103) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:194, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:195; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:437, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:438; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:660, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:661; (104) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:185, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:196; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:428, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:439; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:651, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:662; (105) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:197, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:198; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:440, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:441; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:663, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:664; (106) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:199, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:200; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:442, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:443; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:665, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:666;093699.0208 (107) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:201, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:178; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:444, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:421; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:667, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:644; (108) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:202, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:190; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:445, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:433; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:668, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:656; (109) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:161, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:203; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:404, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:446; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:627, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:669; (110) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:204, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:205; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:447, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:448; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:670, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:671; (111) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:206, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:207; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:449, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:450; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:672, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:673; (112) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:208, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:198; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:451, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:441; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:674, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:664; (113) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:209, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:203; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:452, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:446; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:675, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:669; (114) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:210, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:211; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:453, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:454; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:676, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:677; (115) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:212, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:198; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:455, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:441; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:678, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:664; (116) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:213, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:214; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:456, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:457; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:679, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:680; (117) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:215, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:216; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:458, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:459; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:681, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:682; (118) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:217, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:218; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:460, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:461; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:683, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:684; (119) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:219, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:220; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:462, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:463; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:685, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:686; (120) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:221, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:200; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:464, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:443; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:687, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:666; (121) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:222, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:223; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:465, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:466; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:688, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:689; (122) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:224, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:176; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:467, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:419; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:690, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:642; (123) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:225, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:226; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:468, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:469; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:691, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:692;093699.0208 (124) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:227, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:228; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:470, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:471; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:693, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:694; or (125) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:185, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:229; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:428, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:472; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:651, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:695. In some embodiments, an anti- LTΒR antibody or fragment or derivative thereof comprises a linker region. In some embodiments, the linker connects a VH and a VL region. In some embodiments, the linker connects a VH to a constant region. In some embodiments, the linker comprises an amino acid sequence of any one of SEQ ID NO:2450-2454. In some embodiments, the linker comprises SEQ ID NO:2452. In some embodiments, an anti- LTΒR antibody or fragment or derivative thereof is a stapled single chain antibody fragment (spFv) comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to the amino acid sequence of any one of SEQ ID NO:2190, 2191, and 2204-2449. In some embodiments, the binding domain that specifically binds to LTβR comprises an anti- LTΒR antibody or a fragment or derivative thereof, for instance a single variable domain on a heavy chain (VHH) antibody, comprising a VHH region comprising a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, and a HCDR3, wherein said VHH comprises any of the following:093699.0208 (1) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1042, 1043, and 1044, respectively; (2) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1045, 1046, and 1047, respectively; (3) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1048, 1049, and 1050, respectively; (4) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1042, 1043, and 1044, respectively; (5) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1051, 1052, and 1053, respectively; (6) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1054, 1055, and 1056, respectively; (7) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1057, 1058, and 1059, respectively; (8) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1060, 1043, and 1044, respectively; (9) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:1061, 1043, and 1044, respectively; (10) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1062, 1063, and 1064, respectively; (11) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1065, 1066, and 1067, respectively; (12) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1068, 1069, and 1070, respectively; (13) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1068, 1071, and 1072, respectively; (14) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1073, 1074, and 1064, respectively; (15) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1075, 1076, and 1077, respectively; (16) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1078, 1079, and 1077, respectively; (17) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1062, 1063, and 1064, respectively;093699.0208 (18) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1065, 1080, and 1081, respectively; (19) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1068, 1082, and 1072, respectively; or (20) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1065, 1083, and 1084, respectively.

[0113] In some embodiments, the binding domain that specifically binds to LTβRcomprises an agonistic anti- LTΒR antibody or a fragment or derivative thereof, for instance a single variable domain on a heavy chain (VHH) antibody, comprising a VHH region comprising an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to the amino acid sequence of any one of SEQ ID NO: 230-249.

[0114] According to a particular aspect, provided herein are isolated anti-lymphotoxin betareceptor ( LTΒR) multispecific antibodies or antigen binding fragments thereof. In certain non- limiting embodiments, the binding domain that specifically binds to LTβR comprises an agonistic anti- LTΒR antibody or a fragment or derivative thereof, for instance a single chain antibody fragment (scFv), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, and a HCDR3, and the VL comprises a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3, wherein said VH and VL comprise any of the following: (1) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:696, 697, and 698, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:699, 700, and 701, respectively; (2) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:743, 744, and 745, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:746, 747, and 748, respectively; (3) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:749, 750, and 751, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:752, 753, and 754, respectively; (4) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:749, 750, and 751, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:752, 753, and 754, respectively; (5) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:755, 756, and 757, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:758, 753, and 759, respectively;093699.0208 (6) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:725, 726, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:760, 729, and 730, respectively; (7) (a) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQID NO:761, 762, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:764, 729, and 730, respectively; (8) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:765, 766, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:728, 729, and 767, respectively; (9) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:765, 766, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:728, 729, and 767, respectively; (10) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:768, 769, and 770, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:771, 772, and 773, respectively; (11) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:749, 774, and 775, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:776, 777, and 778, respectively; (12) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:779, 780, and 781, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:782, 783, and 784, respectively; (13) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:785, 786, and 787, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:788, 789, and 790, respectively; (14) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:749, 774, and 775, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:776, 753, and 791, respectively; (15) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:792, 793, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:794, 729, and 795, respectively; ( (16) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:792, 793, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:794, 729, and 795, respectively;093699.0208 (17) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:796, 797, and 798, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 800, and 801, respectively; (18) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:802, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:805, 806, and 807, respectively; (19) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 809, and 810, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:811, 812, and 813, respectively; (20) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 818, and 819, respectively; (21) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:802, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 821, and 822, respectively; (22) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 824, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:825, 821, and 822, respectively; (23) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:826, 827, and 828, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 831, respectively; (24) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:832, 821, and 807, respectively; (25) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:826, 803, and 828, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 831, respectively; (26) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:833, 834, and 835, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:836, 837, and 838, respectively; (27) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 839, and 819, respectively;093699.0208 (28) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:840, 841, and 807, respectively; (29) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 843, and 819, respectively; (30) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively; (31) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (32) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (33) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 852, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:853, 830, and 848, respectively; (34) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:802, 854, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 821, and 822, respectively; (35) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 855, and 856, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 857, and 858, respectively; (36) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 809, and 810, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:811, 812, and 813, respectively; (37) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (38) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively;093699.0208 (39) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:860, 861, and 862, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 863, and 822, respectively; (40) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:864, 865, and 866, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:867, 868, and 819, respectively; (41) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:869, 870, and 871, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 873, and 874, respectively; (42) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:875, 876, and 877, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 841, and 878, respectively; (43) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 879, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (44) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:880, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 859, and 819, respectively; (45) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 879, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (46) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:881, 882, and 883, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (47) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 859, and 819, respectively; (48) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:887, 888, and 889, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:890, 800, and 891, respectively; ; (49) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 892, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 894, respectively;093699.0208 (50) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:881, 882, and 883, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (51) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 892, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 894, respectively; (52) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:864, 865, and 866, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:867, 868, and 819, respectively; (53) (a) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:881, 882, and 895, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (54) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively; (55) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (56) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:896, 897, and 898, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:899, 830, and 848, respectively; (57) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 803, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 830, and 822, respectively; (58) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 901, and 819, respectively; (59) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:826, 902, and 903, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 807, respectively; (60) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively;093699.0208 (61) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively; (62) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (63) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (64) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:909, 910, and 911, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:912, 841, and 822, respectively; (65) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:914, 907, and 908, respectively; (66) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 915, and 916, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:917, 821, and 918, respectively; (67) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:914, 907, and 908, respectively; (68) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:919, 907, and 908, respectively; (69) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (70) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 920, and 921, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:922, 923, and 924, respectively; (71) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:925, 926, and 927, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:928, 818, and 819, respectively;093699.0208 (72) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (73) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:869, 929, and 930, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:931, 907, and 932, respectively; (74) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (75) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (76) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:925, 926, and 927, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:928, 818, and 819, respectively; (77) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:933, 934, and 935, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:936, 818, and 937, respectively; (78) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 938, and 939, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:940, 818, and 941, respectively; (79) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 943, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 863, and 945, respectively; (80) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:946, 947, and 948, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:949, 830, and 950, respectively; (81) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:951, 952, and 953, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:922, 837, and 954, respectively; (82) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively;093699.0208 (83) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 960, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (84) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:962, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (85) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 967, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (86) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:925, 968, and 969, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 830, and 970, respectively; (87) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 837, and 959, respectively; (88) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:749, 971, and 972, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:973, 974, and 975, respectively; (89) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 977, and 959, respectively; (90) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:978, 979, and 980, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 818, and 981, respectively; (91) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:982, 983, and 984, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:985, 986, and 932, respectively; (92) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 987, and 988, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (93) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 989, and 959, respectively;093699.0208 (94) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:990, 991, and 992, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:993, 821, and 994, respectively; (95) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 995, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 945, respectively; (96) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (97) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 987, and 996, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (98) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:925, 968, and 969, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 830, and 970, respectively; (99) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:997, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 857, and 945, respectively; (100) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (101) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 837, and 959, respectively; (102) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:946, 1000, and 1001, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1002, 821, and 1003, respectively; (103) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (104) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 1004, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively;093699.0208 (105) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 1005, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1006, 830, and 1007, respectively; (106) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 987, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (107) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:997, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 857, and 945, respectively; (108) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:962, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (109) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:743, 963, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (110) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 995, and 1008, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1009, 821, and 945, respectively; (111) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 1004, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively; (112) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1010, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (113) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 967, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1011, 1012, and 959, respectively; (114) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively; (115) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1013, 837, and 959, respectively;093699.0208 (116) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:779, 1014, and 1015, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1016, 1017, and 1018, respectively; (117) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1019, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1020, 837, and 959, respectively; (118) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1021, 987, and 1022, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1023, 1024, and 945, respectively; (119) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 1005, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1006, 830, and 1007, respectively; (120) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1025, 1026, and 1027, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1028, 885, and 1029, respectively; (121) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:982, 983, and 984, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:985, 986, and 932, respectively; (122) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1030, 1031, and 1032, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 1033, and 1034, respectively; (123) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 1035, and 959, respectively; (124) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; or (125) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1036, 1037, and 1038, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1039, 1040, and 1041, respectively.

[0115] In some embodiments, provided herein are isolated anti-lymphotoxin beta receptor( LTΒR) multispecific antibodies or antigen binding fragments thereof. In certain non-limiting embodiments, the binding domain that specifically binds to LTβR comprises an agonistic anti- LTΒR antibody or a fragment or derivative thereof, for instance a single chain antibody fragment093699.0208 (scFv), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein said VH and VL comprises any of the following: (1) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:4, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:5; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:250, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:251; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:473, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:474; (2) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:20, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:21; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:264, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:265; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:487, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:488; (3) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:22, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:23; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:266, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:267; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:489, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:490; (4) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:24, and VL comprises an amino acid093699.0208 sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:25; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:268, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:269; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:491, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:492; (5) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:26, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:25; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:270, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:269; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:493, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:492; (6) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:27, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:28; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:271, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:272; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:494, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:495; (7) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:4, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:29; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:250, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid093699.0208 sequence of SEQ ID NO:273; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:473, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:496; (8) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:30, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:31; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:274, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:275; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:497, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:498; (9) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or100% identity to the amino acid sequence of SEQ ID NO:32, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:33; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:276, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:277; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:499, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:500; (10) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:34, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:33; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:278, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:277; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:501, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:500;093699.0208 (11) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:35, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:36; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:279, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:280; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:502, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:503; (12) (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:37, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:38; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:281, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:282; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:504, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:505; (13) (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:39, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:40; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:283, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:284; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:506, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:507; (14) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:41, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:42; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:285, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:286; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:508, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:509; (15) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:37, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:43; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:281, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:287; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:504, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:510; (16) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:44, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:45; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:288, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:289; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:511, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:512; (17) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:44, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:46; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:288, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:290; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:511, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:513; (18) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:47, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:48; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:291, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:292; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:514, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:515; (19) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:49, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:50; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:293, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:294; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:516, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:517; (20) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:51, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:52; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:295, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:296; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:518, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:519; (21) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:53, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:54; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:297, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:298; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:520, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:521; (22) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:55, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:56; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:299, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:300; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:522, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:523; (23) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:57, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:58; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:301, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:302; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:524, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:525; (24) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:59, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:60; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:303, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:304; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:526, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:527; (25) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:61, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:62; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:305, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:306; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:528, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:529; (26) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:62, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:60; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:307, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:304; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:530, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:527; (27) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:64, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:65; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:308, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:309; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:531, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:532;093699.0208 (28) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:66, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:67; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:310, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:311; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:533, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:534; (29) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:68, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:69; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:312, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:313; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:535, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:536; (30) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:66, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:70; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:310, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:314; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:533, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:537; (31) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:71, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:72; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:315, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:316; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:538, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:539; (32) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:73, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:74; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:317, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:318; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:540, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:541; (33) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:75, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:76; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:319, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:320; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:542, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:543; (34) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:77, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:78; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:321, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:322; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID093699.0208 NO:544, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:545; (35) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:79, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:56; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:323, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:300; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:546, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:523; (36) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:80, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:81; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:324, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:325; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:547, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:548; (37) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:82, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:52; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:326, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:296; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:549, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:519; (38) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:73, and VL comprises an093699.0208 amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:76; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:317, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:320; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:540, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:543; (39) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:83, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:84; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:327, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:328; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:550, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:551; (40) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:85, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:86; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:329, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:330; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:552, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:553; (41) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:87, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:88; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:331, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to093699.0208 the amino acid sequence of SEQ ID NO:332; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:554, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:555; (42) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:89, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:90; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:333, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:334; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:556, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:557; (43) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:91, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:92; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:335, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:336; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:558, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:559; (44) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:93, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:94; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:337, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:338; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:560, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:561;093699.0208 (45) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:95, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:96; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:339, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:340; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:562, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:563; (46) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:97, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:98; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:341, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:342; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:564, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:565; (47) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:99, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:100; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:343, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:344; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:566, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:567; (48) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:101, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:102; (b) VH comprises an amino acid sequence having at least 90%,093699.0208 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:345, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:346; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:568, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:569; (49) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:103, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:104; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:347, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:348; or (c) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:570, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:571; (50) (a) VH comprises an amino acid sequence having at least 90%, 95%, 98%,99%, or 100% identity to the amino acid sequence of SEQ ID NO:105, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:106; (b) VH comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity to the amino acid sequence of SEQ ID NO:349, and VL comprises an amino acid sequence having at least 90%, 95%, 98%, 99%, or 100% identity t...

Claims

093699.0208 WHAT IS CLAIMED IS:

1. An antibody or an antigen binding fragment thereof comprising a binding domain that specifically binds to LTβR comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a heavy chain complementarity determining region 1 (HCDR1), a HCDR2, and a HCDR3, and the VL comprises a light chain complementarity determining region 1 (LCDR1), a LCDR2, and a LCDR3, wherein the VH and VL comprise any of the following: (1) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:696, 697, and 698, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:699, 700, and 701, respectively; (2) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:743, 744, and 745, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:746, 747, and 748, respectively; (3) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:749, 750, and 751, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:752, 753, and 754, respectively; (4) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:749, 750, and 751, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:752, 753, and 754, respectively; (5) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:755, 756, and 757, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:758, 753, and 759, respectively; (6) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:725, 726, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:760, 729, and 730, respectively; (7) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:761, 762, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:764, 729, and 730, respectively; (8) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:765, 766, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:728, 729, and 767, respectively;093699.0208 (9) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ IDNO:765, 766, and 727, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:728, 729, and 767, respectively; (10) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:768, 769, and 770, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:771, 772, and 773, respectively; (11) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:749, 774, and 775, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:776, 777, and 778, respectively; (12) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:779, 780, and 781, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:782, 783, and 784, respectively; (13) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:785, 786, and 787, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:788, 789, and 790, respectively; (14) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:749, 774, and 775, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:776, 753, and 791, respectively; (15) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:792, 793, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:794, 729, and 795, respectively; (16) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:792, 793, and 763, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:794, 729, and 795, respectively; (17) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:796, 797, and 798, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 800, and 801, respectively; (18) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:802, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:805, 806, and 807, respectively; ( (19) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 809, and 810, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:811, 812, and 813, respectively;093699.0208 (20) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 818, and 819, respectively; (21) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:802, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 821, and 822, respectively; (22) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 824, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:825, 821, and 822, respectively; (23) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:826, 827, and 828, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 831, respectively; (24) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:832, 821, and 807, respectively; (25) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:826, 803, and 828, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 831, respectively; (26) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:833, 834, and 835, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:836, 837, and 838, respectively; (27) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 839, and 819, respectively; (28) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 803, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:840, 841, and 807, respectively; (29) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 843, and 819, respectively; (30) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively;093699.0208 (31) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (32) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (33) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 852, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:853, 830, and 848, respectively; (34) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:802, 854, and 804, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 821, and 822, respectively; (35) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 855, and 856, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 857, and 858, respectively; (36) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 809, and 810, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:811, 812, and 813, respectively; (37) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 850, and 851, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 830, and 822, respectively; (38) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (39) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:860, 861, and 862, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 863, and 822, respectively; (40) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:864, 865, and 866, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:867, 868, and 819, respectively; (41) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:869, 870, and 871, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 873, and 874, respectively;093699.0208 (42) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:875, 876, and 877, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 841, and 878, respectively; (43) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 879, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (44) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:880, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 859, and 819, respectively; (45) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 879, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (46) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:881, 882, and 883, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (47) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:817, 859, and 819, respectively; (48) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:887, 888, and 889, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:890, 800, and 891, respectively; (49) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 892, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 894, respectively; (50) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:881, 882, and 883, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (51) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 892, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 894, respectively; ( (52) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:864, 865, and 866, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:867, 868, and 819, respectively;093699.0208 (53) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:881, 882, and 895, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:884, 885, and 886, respectively; (54) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively; (55) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (56) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:896, 897, and 898, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:899, 830, and 848, respectively; (57) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 803, and 893, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 830, and 822, respectively; (58) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 901, and 819, respectively; (59) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:826, 902, and 903, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:829, 830, and 807, respectively; (60) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:814, 815, and 816, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:842, 859, and 819, respectively; (61) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:844, 845, and 846, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:847, 818, and 848, respectively; (62) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (63) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively;093699.0208 (64) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:909, 910, and 911, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:912, 841, and 822, respectively; (65) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:914, 907, and 908, respectively; (66) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 915, and 916, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:917, 821, and 918, respectively; (67) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:914, 907, and 908, respectively; (68) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 913, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:919, 907, and 908, respectively; (69) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (70) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:849, 920, and 921, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:922, 923, and 924, respectively; (71) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:925, 926, and 927, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:928, 818, and 819, respectively; (72) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (73) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:869, 929, and 930, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:931, 907, and 932, respectively; (74) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively;093699.0208 (75) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:823, 904, and 905, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:906, 907, and 908, respectively; (76) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:925, 926, and 927, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:928, 818, and 819, respectively; (77) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:933, 934, and 935, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:936, 818, and 937, respectively; (78) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:808, 938, and 939, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:940, 818, and 941, respectively; (79) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 943, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 863, and 945, respectively; (80) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:946, 947, and 948, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:949, 830, and 950, respectively; (81) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:951, 952, and 953, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:922, 837, and 954, respectively; (82) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively (83) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 960, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (84) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:962, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (85) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 967, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively;093699.0208 (86) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:925, 968, and 969, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 830, and 970, respectively; (87) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 837, and 959, respectively; (88) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:749, 971, and 972, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:973, 974, and 975, respectively; (89) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 977, and 959, respectively; (90) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:978, 979, and 980, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 818, and 981, respectively; (91) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:982, 983, and 984, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:985, 986, and 932, respectively; (92) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 987, and 988, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (93) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 989, and 959, respectively; (94) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:990, 991, and 992, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:993, 821, and 994, respectively; (95) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 995, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 945, respectively; (96) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively;093699.0208 (97) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 987, and 996, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (98) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:925, 968, and 969, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:799, 830, and 970, respectively; (99) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:997, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 857, and 945, respectively; (100) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (101) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:872, 837, and 959, respectively; (102) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:946, 1000, and 1001, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1002, 821, and 1003, respectively; (103) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; (104) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 1004, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively; (105) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 1005, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1006, 830, and 1007, respectively; (106) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 987, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 821, and 966, respectively; (107) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:997, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 857, and 945, respectively;093699.0208 (108) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:962, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (109) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:743, 963, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (110) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 995, and 1008, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1009, 821, and 945, respectively; (111) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 1004, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively; (112) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1010, 963, and 964, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:965, 863, and 966, respectively; (113) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 967, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1011, 1012, and 959, respectively; (114) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 998, and 999, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:820, 857, and 945, respectively; (115) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:976, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1013, 837, and 959, respectively; (116) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:779, 1014, and 1015, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1016, 1017, and 1018, respectively; (117) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1019, 956, and 961, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1020, 837, and 959, respectively; (118) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1021, 987, and 1022, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1023, 1024, and 945, respectively;093699.0208 (119) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:942, 1005, and 944, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1006, 830, and 1007, respectively; (120) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1025, 1026, and 1027, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1028, 885, and 1029, respectively; (121) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:982, 983, and 984, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:985, 986, and 932, respectively; (122) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1030, 1031, and 1032, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:900, 1033, and 1034, respectively; (123) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 1035, and 959, respectively; (124) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:955, 956, and 957, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:958, 837, and 959, respectively; and (125) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences ofSEQ ID NO:1036, 1037, and 1038, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1039, 1040, and 1041, respectively.

2. The antibody or antigen binding fragment of claim 1, wherein the binding domain that specifically binds to LTβR comprises any one of the following: (1) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:4, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:5; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:250, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:251; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:473, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:474; (2) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:20, and VL comprises an amino acid sequence having at least093699.0208 90% identity to the amino acid sequence of SEQ ID NO:21; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:264, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:265; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:487, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:488; (3) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:22, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:23; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:266, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:267; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:489, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:490; (4) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:24, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:25; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:268, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:269; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:491, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:492; (5) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:26, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:25; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:270, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:269; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:493, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:492; (6) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:27, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:28; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:271, and VL093699.0208 comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:272; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:494, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:495; (7) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:4, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:29; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:250, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:273; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:473, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:496; (8) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:30, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:31; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:274, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:275; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:497, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:498; (9) (a) VH comprises an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:32, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:33; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:276, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:277; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:499, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:500; (10) VH comprises an amino acid sequence having at least 90% identity to theamino acid sequence of SEQ ID NO:34, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:33; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:278, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:277; or (c) VH comprises an amino acid sequence having at least 90% identity093699.0208 to the amino acid sequence of SEQ ID NO:501, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:500; (11) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:35, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:36; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:279, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:280; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:502, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:503; (12) (b) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:37, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:38; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:281, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:282; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:504, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:505; (13) (c) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:39, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:40; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:283, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:284; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:506, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:507; (14) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:41, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:42; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:285, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:286; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:508, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:509;093699.0208 (15) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:37, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:43; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:281, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:287; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:504, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:510; (16) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:44, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:45; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:288, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:289; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:511, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:512; (17) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:44, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:46; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:288, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:290; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:511, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:513; (18) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:47, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:48; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:291, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:292; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:514, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:515; (19) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:49, and VL comprises an amino acid sequence having093699.0208 at least 90% identity to the amino acid sequence of SEQ ID NO:50; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:293, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:294; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:516, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:517; (20) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:51, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:52; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:295, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:296; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:518, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:519; (21) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:53, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:54; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:297, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:298; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:520, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:521; (22) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:55, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:56; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:299, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:300; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:522, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:523; (23) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:57, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:58; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:301, and093699.0208 VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:302; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:524, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:525; (24) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:59, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:60; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:303, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:304; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:526, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:527; (25) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:61, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:62; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:305, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:306; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:528, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:529; (26) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:62, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:60; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:307, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:304; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:530, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:527; (27) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:64, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:65; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:308, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:309; or (c) VH comprises an amino acid sequence having at least 90% identity093699.0208 to the amino acid sequence of SEQ ID NO:531, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:532; (28) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:66, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:67; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:310, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:311; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:533, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:534; (29) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:68, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:69; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:312, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:313; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:535, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:536; (30) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:66, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:70; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:310, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:314; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:533, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:537; (31) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:71, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:72; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:315, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:316; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:538, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:539;093699.0208 (32) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:73, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:74; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:317, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:318; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:540, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:541; (33) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:75, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:76; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:319, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:320; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:542, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:543; (34) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:77, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:78; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:321, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:322; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:544, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:545; (35) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:79, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:56; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:323, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:300; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:546, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:523; (36) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:80, and VL comprises an amino acid sequence having093699.0208 at least 90% identity to the amino acid sequence of SEQ ID NO:81; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:324, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:325; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:547, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:548; (37) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:82, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:52; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:326, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:296; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:549, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:519; (38) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:73, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:76; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:317, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:320; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:540, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:543; (39) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:83, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:84; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:327, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:328; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:550, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:551; (40) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:85, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:86; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:329, and093699.0208 VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:330; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:552, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:553; (41) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:87, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:88; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:331, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:332; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:554, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:555; (42) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:89, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:90; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:333, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:334; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:556, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:557; (43) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:91, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:92; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:335, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:336; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:558, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:559; (44) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:93, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:94; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:337, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:338; or (c) VH comprises an amino acid sequence having at least 90% identity093699.0208 to the amino acid sequence of SEQ ID NO:560, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:561; (45) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:95, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:96; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:339, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:340; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:562, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:563; (46) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:97, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:98; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:341, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:342; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:564, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:565; (47) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:99, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:100; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:343, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:344; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:566, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:567; (48) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:101, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:102; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:345, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:346; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:568, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:569;093699.0208 (49) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:103, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:104; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:347, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:348; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:570, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:571; (50) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:105, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:106; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:349, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:350; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:572, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:573; (51) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:99, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:107; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:343, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:351; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:566, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:574; (52) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:108, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:106; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:352, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:350; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:575, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:573; (53) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:109, and VL comprises an amino acid sequence having093699.0208 at least 90% identity to the amino acid sequence of SEQ ID NO:110; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:353, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:354; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:576, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:577; (54) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:111, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:100; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:355, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:344; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:578, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:567; (55) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:112, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:72; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:356, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:316; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:538, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:539; (56) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:113, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:84; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:357, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:328; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:579, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:551; (57) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:114, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:115; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID093699.0208 NO:358, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:359; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:580, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:581; (58) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:116, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:117; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:360, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:361; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:582, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:583; (59) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:113, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:118; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:357, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:362; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:579, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:584; (60) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:119, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:120; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:363, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:364; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:585, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:586; (61) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:121, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:84; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:365, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:328; or (c) VH comprises an amino acid sequence having at least 90% identity093699.0208 to the amino acid sequence of SEQ ID NO:587, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:551; (62) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:122, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:72; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:315, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:316; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:588, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:539; (63) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:123, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:124; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:366, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:367; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:589, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:590; (64) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:125, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:126; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:368, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:369; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:591, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:592; (65) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:127, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:128; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:370, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:371; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:593, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:594;093699.0208 (66) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:129, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:130; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:372, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:373; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:595, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:596; (67) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:131, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:132; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:374, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:375; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:597, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:598; (68) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:133, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:130; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:376, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:373; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:599, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:596; (69) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:134, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:135; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:377, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:378; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:600, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:601; (70) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:136, and VL comprises an amino acid sequence having093699.0208 at least 90% identity to the amino acid sequence of SEQ ID NO:124; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:379, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:367; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:602, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:590; (71) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:137, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:138; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:380, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:381; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:603, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:604; (72) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:139, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:140; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:382, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:383; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:605, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:606; (73) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:141, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:124; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:384, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:367; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:607, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:590; (74) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:142, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:143; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID093699.0208 NO:385, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:386; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:608, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:609; (75) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:144, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:145; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:387, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:388; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:610, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:611; (76) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:144, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:124; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:387, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:367; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:610, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:591; (77) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:146, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:140; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:389, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:383; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:612, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:606; (78) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:147, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:148; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:390, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:391; or (c) VH comprises an amino acid sequence having at least093699.0208 90% identity to the amino acid sequence of SEQ ID NO:613, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:614; (79) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:149, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:150; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:392, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:393; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:615, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:616; (80) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:151, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:152; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:394, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:395; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:617, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:618; (81) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:153, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:154; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:396, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:397; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:619, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:620; (82) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:155, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:156; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:398, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:399; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:621, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:622;093699.0208 (83) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:157, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:158; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:400, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:401; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:623, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:624; (84) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:159, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:160; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:402, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:403; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:625, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:626; (85) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:161, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:162; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:404, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:405; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:627, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:628; (86) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:163, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:164; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:406, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:407; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:629, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:630; (87) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:165, and VL comprises an amino acid sequence having093699.0208 at least 90% identity to the amino acid sequence of SEQ ID NO:166; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:408, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:409; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:631, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:632; (88) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:167, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:168; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:410, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:411; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:633, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:634; (89) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:169, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:170; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:412, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:413; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:635, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:636; (90) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:171, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:172; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:414, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:415; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:637, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:638; (91) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:173, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:174; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID093699.0208 NO:416, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:417; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:639, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:640; (92) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:175, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:176; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:418, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:419; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:641, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:642; (93) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:177, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:178; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:420, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:421; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:643, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:644; (94) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:179, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:180; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:422, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:423; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:645, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:646; (95) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:181, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:182; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:424, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:425; or (c) VH comprises an amino acid sequence having at least093699.0208 90% identity to the amino acid sequence of SEQ ID NO:647, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:648; (96) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:183, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:184; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:426, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:427; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:649, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:650; (97) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:185, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:186; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:428, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:429; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:651, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:652; (98) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:187, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:178; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:430, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:421; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:653, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:644; (99) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:165, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:188; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:408, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:431; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:631, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:654;093699.0208 (100) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:189, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:190; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:432, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:433; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:655, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:656; (101) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:185, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:191; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:428, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:434; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:651, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:657; (102) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:192, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:193; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:435, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:436; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:658, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:659; (103) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:194, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:195; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:437, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:438; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:660, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:661; (104) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:185, and VL comprises an amino acid sequence having093699.0208 at least 90% identity to the amino acid sequence of SEQ ID NO:196; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:428, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:439; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:651, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:662; (105) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:197, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:198; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:440, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:441; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:663, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:664; (106) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:199, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:200; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:442, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:443; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:665, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:666; (107) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:201, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:178; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:444, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:421; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:667, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:644; (108) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:202, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:190; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID093699.0208 NO:445, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:433; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:668, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:656; (109) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:161, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:203; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:404, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:446; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:627, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:669; (110) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:204, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:205; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:447, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:448; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:670, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:671; (111) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:206, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:207; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:449, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:450; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:672, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:673; (112) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:208, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:198; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:451, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:441; or (c) VH comprises an amino acid sequence having at least093699.0208 90% identity to the amino acid sequence of SEQ ID NO:674, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:664; (113) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:209, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:203; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:452, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:446; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:675, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:669; (114) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:210, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:211; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:453, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:454; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:676, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:677; (115) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:212, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:198; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:455, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:441; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:678, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:664; (116) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:213, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:214; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:456, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:457; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:679, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:680;093699.0208 (117) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:215, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:216; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:458, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:459; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:681, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:682; (118) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:217, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:218; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:460, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:461; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:683, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:684; (119) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:219, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:220; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:462, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:463; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:685, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:686; (120) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:221, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:200; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:464, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:443; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:687, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:666; (121) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:222, and VL comprises an amino acid sequence having093699.0208 at least 90% identity to the amino acid sequence of SEQ ID NO:223; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:465, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:466; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:688, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:689; (122) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:224, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:176; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:467, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:419; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:690, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:642; (123) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:225, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:226; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:468, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:469; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:691, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:692; (124) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:227, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:228; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:470, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:471; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:693, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:694; and (125) (a) VH comprises an amino acid sequence having at least 90% identity tothe amino acid sequence of SEQ ID NO:185, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:229; (b) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID093699.0208 NO:428, and VL comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:472; or (c) VH comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:651, and VL comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or 100% identity to the amino acid sequence of SEQ ID NO:

695.

3. The antibody or antigen binding fragment thereof of claim 1, wherein the binding domain that specifically binds to LTβR comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NO:2199, 2200, and 2213-2458.

4. The antibody or antigen binding fragment thereof of claim 1, wherein the binding domain that specifically binds to LTβR comprises: (a) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:696, 697, and 698, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:699, 700, and 701, respectively; (b) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1085, 1086, and 698, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:699, 700, and 701, respectively; (c) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1212, 1213, and 698, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:699, 700, and 701, respectively; (d) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1379, 1380, and 1381, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1382, 1383, and 701, respectively; or (e) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:1700, 1701, and 1702, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:1703, 1704, and 1705, respectively.

5. The antibody or antigen binding fragment thereof of claim 1, wherein the binding domain that specifically binds to LTβR comprises: (a) a VH comprising an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:4, and a VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:5;093699.0208 (b) VH comprising an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:250, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:251; or (c) VH comprising an amino acid sequence having at least 90% identity to the aminoacid sequence of SEQ ID NO:473, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:

474.

6. The antibody or antigen binding fragment thereof of claim 1, wherein the binding domain that specifically binds to LTβR comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2199.

7. The antibody or antigen binding fragment thereof of claim 1, wherein the binding domain that specifically binds to LTβR comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2200.

8. The antibody or antigen binding fragment thereof of claim 1, wherein the antibody or the antigen binding fragment thereof comprises one or two binding domains that specifically bind to LTβR.

9. The antibody or antigen binding fragment thereof of any one of claims 1-8, wherein the antibody is a multispecific specific antibody comprising a first binding domain that specifically binds to a first antigen, and a second binding domain that specifically binds to a second antigen, wherein the first binding domain specifically binds to lymphotoxin beta receptor (LTβR) or a fragment or a derivative thereof and the second binding domain that specifically binds to a second antigen specifically binds to a tumor-associated antigen (TAA).

10. The antibody or antigen binding fragment thereof of claim 9, wherein the binding domain selectively binds to the TAA specifically binds to Extra-Domain B (EDB), epidermal growth factor (EGFR), prostate-specific membrane antigen (PSMA), or mesothelin (MSLN).

11. The antibody or antigen binding fragment thereof of claim 9, wherein the binding domain that specifically binds to TAA is selected from the group consisting of: (A) binding domain that specifically binds EDB comprising HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:702, 703, and 704, respectively;093699.0208 and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:705, 706, and 707, respectively; (B) a binding domain that specifically binds EGFR comprising HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:708, 709, and 710, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:711, 712, and 713, respectively; or (C) a binding domain that specifically binds to MSLN comprising HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:714, 715, and 716, respectively; and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:717, 718, and 719, respectively.

12. The antibody or antigen binding fragment thereof of claim 9, wherein the binding domain that specifically binds to the TAA is selected from the group consisting of: (A) a binding domain that specifically binds to EDB comprising a VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:6, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:7; (b) VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:252, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:253; or (c) VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:475, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:476; (B) a binding domain that specifically binds to EGFR comprising a VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:8, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:9; (b) VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:254, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:255; or (c) VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:477, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:478; or (C) a binding domain that specifically binds to MSLN comprising a VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:10, and VL comprising an amino acid sequence having at least 90% identity to the amino acid093699.0208 sequence of SEQ ID NO:11; (b) VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:256, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:257; or (c) VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:481, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:

482.

13. The antibody or antigen binding fragment thereof of claim 10, wherein the binding domain that specifically binds to EDB comprises HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NO:702, SEQ ID NO:703, and SEQ ID NO:704, respectively, and LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NO:705, SEQ ID NO:706, and SEQ ID NO:707, respectively.

14. The antibody or antigen binding fragment thereof of claim 10, wherein the binding domain that specifically binds to EDB comprises a VH comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:6, and VL comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:

7.

15. The antibody or antigen binding fragment thereof of claim 10, wherein the antibody or the antigen binding fragment thereof comprises one or two binding domains that specifically bind to EDB.

16. The multispecific antibody or antigen binding fragment thereof of any one of claims 9- 15, wherein the antibody or the antigen binding fragment thereof comprises two binding domains that specifically bind to LTΒR and two binding domains that specifically bind to EDB, wherein the two binding domains that specifically bind to LTΒR comprise: (1) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2103 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2087; (2) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2105 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2087;093699.0208 (3) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2107 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2087; (4) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2159 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2116; (5) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2160 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2116; (6) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2162 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2116; (7) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2174 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2087; (8) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2175 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2087; (9) two heavy chain-scFv fusion peptides comprising an amino acid sequence havingat least 90% identity to the amino acid sequence of SEQ ID NO:2176 forming two binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2087; (10) two heavy chain-scFv fusion peptides comprising an amino acid sequencehaving at least 90% identity to the amino acid sequence of SEQ ID NO:2177 forming two binding domain with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2116; or (11) two heavy chain-scFv fusion peptides comprising an amino acid sequencehaving at least 90% identity to the amino acid sequence of SEQ ID NO:2179 forming two093699.0208 binding domains with two light chains comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:2087.

17. The multispecific antibody or antigen binding fragment thereof of any one of claims 9- 16, wherein the antibody comprises two binding domains that specifically bind to LTβR and further comprises K248E and T437R (RE) mutations in an IgG1 Fc domain.

18. The multispecific antibody or antigen binding fragment thereof of claims 9-17, wherein the antibody is bispecific.

19. A synthetic nucleic acid molecule encoding the the antibody or antigen binding fragment thereof of any one of claims 1-18.

20. A vector comprising the synthetic nucleic acid molecule of claim 19.

21. An isolated host cell comprising the synthetic nucleic acid molecule of claim 19 or the vector of claim 20.

22. A pharmaceutical composition comprising the antibody or antigen binding fragment thereof of any one of claims 1-18 and a pharmaceutically acceptable carrier.

23. A method of producing the the antibody or antigen binding fragment thereof of any one of claims 1-18 comprising the steps of: a) contacting a host cell with the synthetic nucleic acid molecule of claim 19or the vector of claim 20; b) culturing the host cell; andc) harvesting the molecule.

23. A method of treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount the antibody or the antigen binding fragment thereof of any one of claims 1-18, the nucleic acid molecule of claim 19, or the vector of claim 20.

24. The method of claim 23, further comprising administering a second therapeutic agent selected from the group consisting of an anti-CD20 mAb, an anti-TIM-3 mAb, an anti-CTLA-4 antibody, an anti-PD-L1 antibody, an anti-PD-1 antibody, a PD-1 / PD-L1 therapy, Indoleamine-093699.0208 pyrrole 2,3-dioxygenase (IDO), an anti-OX40 antibody, an anti-GITR antibody, an anti-CD40 antibody, an anti-CD38 antibody, a cytokine, an oncolytic virus, a TLR agonist, a STING agonist, and combinations thereof.

25. A method of activating non-canonical NF-κB signaling in a subject in need thereof, comprising administering to the subject an effective amount the antibody or the antigen binding fragment thereof of any one of claims 1-18, the nucleic acid molecule of claim 19, or the vector of claim 20.

26. A method of inducing tertiary lymphoid structure (TLS) neogenesis in a subject in need thereof, comprising administering to the subject an effective amount the antibody or the antigen binding fragment thereof of any one of claims 1-18, the nucleic acid molecule of claim 19, or the vector of claim 20.

Images